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Abstract 
Characterization of Murine Cytomegalovirus dUTPase homolog, M72, 
and investigations into novel interacting host factors  
Sandhya Gopal, Ph.D. 
The University of Texas at Austin, 2018 
Supervisor:  Jason W. Upton 
Abstract: Human cytomegaloviruses (HCMV), a beta herpesvirus, presents a 
challenge in terms of morbidity and mortality associated with immunocompromised 
patients and congenital infections. One approach to tackle issues associated with HCMV 
infection is to understand multiple facets of host-pathogen interactions. However, since 
herpesviruses are species specific, it becomes imperative to utilize small animal model 
systems to investigate in the context of natural host. I utilized a genetically and biologically 
related Murine cytomegalovirus (MCMV) with mice as the small model system. For my 
dissertation research, I focused on the MCMV dUTPase homolog M72. The dUTPase 
homologs in the herpesvirus family are classified as core genes and significant roles are 
ascribed to them. However, little was known specifically about the role of dUTPase 
homologs among beta herpesviruses.  Human cytomegalovirus (HCMV) UL72 and murine 
cytomegalovirus (MCMV) M72 were designated as dUTPases based on limited sequence 
and positional homology. I found that M72 is not enzymatically active as a dUTPase and 
is expressed as a leaky-late gene product with multiple protein isoforms. Additionally, M72 
viii 
augments virus replication in vitro and in the acute phase in vivo. To begin to understand 
M72 function, I took a proteomics approach and identified interacting host protein partners. 
I identified and confirmed interaction of M72 with the eukaryotic chaperonin tailless 
complex protein-1 (TCP-1) ring complex (TRiC) or chaperonin containing tailless complex 
polypeptide 1 (CCT). Accumulating biochemical evidence indicates M72 forms homo-
oligomers and is a substrate of TRiC/CCT. To explore the role of M72 beyond protein 
folding, I also identified components of Carbon catabolite repression 4 (CCR4)-negative 
on TATA-less (NOT) or CCR4-NOT complex, including the 182-kDa Tankyrase 1 binding 
protein (TAB182) as M72 candidate interacting proteins. My current work suggests that 
CCR4-NOT complex subunit 1 (CNOT1) is necessary for MCMV replication. 
Additionally, M72 mediates its own function at least partially via CNOT1 during virus 
replication.  
Taken together, this research provides the first evidence of a beta herpesvirus 
dUTPase homolog’s contribution to viral replication. My dissertation research has helped 
uncover host proteins novel for herpesviruses as interacting partners. In addition, one of 
these host factors, CNOT1, contributes to M72 mediated function. 
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Chapter 1:  Introduction1 
1.1 OVERVIEW 
In this chapter, I will review the following topics relevant to my dissertation – a 
general overview of the family of Herpesviruses, the virus of my particular interest, Human 
Cytomegalovirus (HCMV) and small animal model systems to study HCMV. I will then 
discuss the model organism of my interest Murine Cytomegalovirus (MCMV), focus on 
the gene family of relevance to my dissertation, herpes viral dUTPase homologs, and 
specifically focus on the MCMV designated dUTPase homolog M72. I will subsequently 
review some novel host factors that I identified as M72 interacting proteins – 1) host 
chaperonin tailless complex protein -1 (TCP-1) ring complex (TRiC)/chaperonin 
containing tailless complex polypeptide 1 (CCT) and 2) Carbon catabolite repression 4 
(CCR4)-negative on TATA-less (NOT) or CCR4-NOT transcriptional complex. 
1.2 HERPESVIRUSES  
1.2.1 Introduction to Herpesviruses 
Herpesviruses are large enveloped viruses. The name is derived from the Greek 
word herpein, meaning, “to creep”, referring to the recurring infections due to herpetic 
sores in the mouth and groin.  Herpesviruses are ubiquitous in nature and infect both 
vertebrate and non-vertebrate species. To date more than 130 herpesviruses are 
characterized, and eight have been routinely isolated from humans [2]. In general, viruses 
in this family are highly species specific with the natural host range of individual viruses 
1 Portions of section 1.7.2 reviewing ‘Herpesviral dUTPase homologs’ are from my paper [1]. Gopal, S., et 
al., Murine cytomegalovirus M72 promotes acute virus replication in vivo and is a substrate of the 
TRiC/CCT complex. Virology, 2018. 522: p. 92-105. I wrote the initial manuscript and primarily Jason W. 
Upton (JWU) edited it.  
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restricted to a single species. Herpesviruses display both lytic and latent stages in their life 
cycles. Disease manifestations in humans range from mild fever and rash to cancer across 
this family. 
1.2.2 Classification of Herpesviruses 
The order Herpesvirales is classified into three families of which the family 
Herpesviridae includes viruses infecting mammals, birds and reptiles. Herpesviridae are 
studied most commonly and divided into three subfamilies: Alphaherpesvirnae, 
Betaherpesvirinae and Gammaherpesvirinae [3, 4]. This classification is based on genomic 
sequences and shared biological properties. It also serves the purpose of explaining 







Alphaherpesvirinae 1. Very short (hours) infection cycle 
2. Establishment of latency in sensory 
neuron 
Betaherpesvirinae 1. Very long (days) reproductive 
cycle 
2. Establishment of latency in 
secretory glands, 
reticuloendothelial cells and 
kidneys 
Gammaherpesvirinae 1. Primary infection is following by 
periodic reactivation  
2. Latency in B cells 
3. Unique due to its association with 
human malignant tumors 
 
Table 1.1: General properties of subfamilies of Herpesviridae. 




1.2.3 Structure of Herpesviruses 
Membership in the Herpesviridae family is dependent on virus morphology. 
Virions are spherical and consists of four components – core, capsid, tegument, and 
envelope. The core consists of a single copy of double stranded linear DNA molecule 
packed tightly. Cores are surrounded by an icosahedron capsid with 162 capsomeres, 
consisting of 12 pentons and 150 hexons [5]. The tegument is an amorphous layer of 
proteins surrounding the capsid. The outermost layer consists of the viral envelope, studded 
with viral membrane glycoproteins and some cellular proteins. The composition of the 
tegument and envelope varies widely across the family. 
1.2.4 Infection cycle in Herpesviruses 
After initial infection of host cells, viral transcription, genome replication and 
capsid assembly occurs in the nucleus. Gene expression is temporally regulated with a 
sequential cascade of: (1) immediate-early genes, which make regulatory proteins; (2) early 
genes, which make enzymes for DNA replication; (3) late genes, which generate structural 
proteins. Virions bud out from the nucleus or the endoplasmic reticulum, and the tegument 
and envelope are acquired during this process. The virions are transported to the cell 
membrane, and the host cell dies as the virions are released [2].  
Alternatively, latent virus can be maintained during which no replication occurs, 
and only few viral proteins are expressed. Latency is broadly characterized by – (1) viral 
genome maintenance in infected cells and (2) avoidance of the immune system and cell 
death. In the event of cellular or environmental stress, latently infected cells can reactivate 
from this state and express gene products sequentially [6].   
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1.3 HUMAN HERPESVIRUSES 
Nine herpesviruses infect humans and are spread across all three subfamilies. 
Prevalence of herpesviruses is determined by serology [7] and it varies depending on the 
type of virus. These viruses are believed to have co-evolved over a long period of 
evolutionary history with their hosts. Hence, their interactions with the host are typically 
benign compared to their more zoonotic counterparts like Severe Acute Respiratory 
Syndrome (SARS) coronavirus, Ebola and Avian influenza. Thus, a healthy individual will 
have minor symptoms due to infection with herpesviruses. Chickenpox blisters and herpes 
cold sores are exceptions to this. Disease manifestations include mild fever, rash, and 
infrequently cancer (Table 1.2). Human herpesviruses are typically restrained by an 
immunocompetent host after which they will become latent. Alpha herpesviruses become 
latent in neurons, whereas cells of monocyte lineage are believed to be involved in the 
latency of beta herpesviruses while gamma herpesviruses become latent in lymphocytes 
[6]. Transmission of human herpesviruses is usually by close contact with bodily secretions 
and typically happens early in life [8].  
Currently there are vaccines for prevention of Varicella-zoster virus (VZV) – a live 
attenuated vaccine for prevention of varicella (or chicken pox) and a therapeutic vaccine 
for herpes zoster (or shingles) [9, 10]. Other promising vaccine candidates for Herpesvirus 
Simplex Virus (HSV)-1, 2 and HCMV are in several stages of clinical trials. Of these, 
progress towards the HCMV vaccine is a very active area of research with focus on a major 
HCMV glycoprotein gB as a candidate immunogen [11]. Development of Epstein-Barr 
virus (EBV) vaccines has been slower, yet EBV glycoprotein gp350 recombinant protein 
based candidate vaccines are in different phases of trials [12].  
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Some of the human herpesviruses are amenable to antiviral treatment. Acyclovir is 
preferred for HSV and VZV infections in immunocompromised hosts [13]. Valaciclovir 
and Famciclovir are licensed for shingles in the elderly [14], whereas Ganciclovir and 





Table 1.2: Human Herpesviruses and their disease manifestations. 




Subfamily Common Name Disease Transmission 
route 
HHV 1  alpha Herpesvirus 






(Oral or sexual 
route) 
HHV 2  alpha Herpesvirus 










HHV 3  alpha Varicella-zoster 
virus (VZV) 
Chickenpox, shingles Respiratory, 
intimate contact 
(including sexual) 

























beta Roseola virus  
 
Roseola infantum 
(sixth disease or 
exanthem subitum) 
Respiratory and 
intimate contact ? 
HHV 7  beta Roseola virus  Roseola in infants, 
encephalopathy 
Unknown 












1.4 HUMAN CYTOMEGALOVIRUS  
Human cytomegalovirus (HCMV) or Human Herpesvirus 5 (HHV-5) and other 
animal cytomegaloviruses belong to the sub-family Betaherpesvirinae and genus 
Cytomegalovirus. HCMV is a significant human pathogen, especially in developed 
countries. The name cytomegalovirus is derived from the characteristic enlargement of 
infected cells (cytomegaly) and presence of nuclear inclusion bodies (typically aggregates 
of stable proteins).  
1.4.1 History of Cytomegalovirus 
The German scientist Hugo Ribbert first observed HCMV in 1881 in tissue sections 
of kidney and parotid gland but was not able to identify the etiological agent. Subsequent 
German scientists in 1904 described, ‘eccentrically-placed nucleus surrounded by a halo’ 
in sections of kidneys, liver and lungs of fetuses, which was interpreted as a protozoan 
infection. These are probably the first descriptions of cytomegalic inclusions in published 
literature, but the viral etiology of these observations was not yet known (summarized by 
Ho Monto, 2008 [17]). Subsequent findings of similar inclusion bodies from herpes zoster 
lesions [18, 19] led to suspicions of a viral etiology from a group of related viruses (now 
known as Herpesviruses). At this point in scientific history, though the general concept of 
virus was accepted, the very nature of virus itself was not clearly understood. Later, 
observations of inclusion bodies from 25 rare cases of congenital infection characterized 
by petechiae, hepatosplenomegaly and intracerebral calcification led to the introduction of 
the term - generalized cytomegalic inclusion disease (CID). With the advent of mammalian 
cell culture technique [20], the challenge of culturing HCMV was tackled. Dr. Margaret G. 
Smith made pioneering efforts in isolating cytomegaloviruses. Eventually, three scientists 
– Margaret G. Smith, Wallace P. Rowe and Thomas H. Weller independently isolated 
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cytomegaloviruses from 1956–57. They exchanged the isolated agents with each other and 
collaborated to confirm the similarity of agents [21-23]. Thomas H. Weller suggested the 
name cytomegalovirus [24, 25].   
1.4.3 Characteristics of HCMV  
HCMV structure includes features typical of the herpesvirus family as illustrated in 
Figure 1.1. The virion is about 230 nm in diameter and consists of an icosahedral capsid, a 
tegument and a trilaminate membrane envelope. The capsid encloses a linear, double-
stranded DNA genome approximately 236 kb in size (in wild type virus) [26], which is the 
largest among human herpesviruses. The capsid is approximately 110 nm in diameter and 
made up of four integral protein species - pUL46, pUL80.5, pUL85 and pUL104 – in the 
framework of 162 capsomeres. The tegument is an amorphous layer, approximately 50 nm 
thick; however, some structuring of tegument proteins close to the capsid has been 
observed [27]. This layer includes about 79 viral proteins, although only 35 are found 
abundantly [28, 29]. The outermost envelope is about 10 nm thick, and contains about ten 
abundant viral proteins. Less-abundant viral and host proteins, phospholipids, polyamines 
and small RNAs are also included in the composition of the tegument and envelope [30].  
Particle composition varies depending on source, method of preparation and nature 
(sensitivity) of analysis. Apart from virions, five other types of viral particles have been 
isolated from CMV infected cells as summarized in Table 1.3 [30, 31]. Briefly A-, B- and 
C- type capsids can be obtained by lysing CMV infected cells with NP-40, whereas non-
infectious enveloped particles (NIEP) and Dense Bodies (DB) can be recovered from 
culture supernatants of CMV infected cells. In general, HCMV is sensitive to lipid-
10 
 
dissolving agents, low pH conditions and heat. It is not stable at -20ºC but must be stored 






Figure 1.1: Schematic of HCMV structure 
This figure illustrates the general structure of Cytomegaloviruses (HCMV and other 
animal CMV). The double-stranded linear DNA genome is tightly packed inside an 
icosahedral capsid surrounded by a tegument layer with several proteins. The tegument is 









Figure 1.2: Five types of HCMV particles. 




1.4.4 HCMV Replication 
HCMV infects a wide variety of cells including fibroblasts, endothelial cells, 
smooth muscle cells, epithelial cells, monocytes/macrophages, although human fibroblasts 
constitute the major cell target that aids replication of virus [32]. The steps involved during 
virus multiplication are illustrated in Figure 1.2. Multiple cellular receptors like epidermal 
growth factor receptor (EGFR) [33], platelet derived growth factor receptor alpha 
(PDGFRα) [34] and bone marrow stromal cell antigen 2 (BST2)/Tetherin [35] have been 
described in literature. Depending on cell type and strain of virus (laboratory strain AD169, 
Towne or clinical strain TR) both fusion at the plasma membrane and endosomal 
acidification can facilitate entry [36-38]. Viral glycoproteins gB [39], gM/gN [40], gH/gL 
[41] and gO  [42] or UL128-UL131  [43-45] are some important examples that mediate 
entry depending on cell type. After interaction of viral glycoproteins with the host cell, and 
initial fusion events, the capsid is deposited in the cytoplasm. Tegument proteins are also 
released in this step into the cytoplasm and mediate roles during early stages of infection 
[46]. Within a short time, the capsid is transported to the nucleus primarily via the 
microtubule network [47]. The capsid docks at the nuclear pore complex and the genome 
is released into the nucleus where viral transcription, genome replication and encapsidation 
occur. This cascade of events occurs in a sequentially and temporally regulated manner, 
similar to other herpesviruses. Immediate-early genes are transcribed first, and they do not 
require de novo protein synthesis. These gene products facilitate/regulate the early genes, 
leading to DNA replication. Subsequently, late genes are made [48, 49]. The viral capsid 
is assembled inside the nucleus and transported to the cytoplasm where virion assembly 
and maturation is orchestrated by the cytoplasmic viral assembly complex (AC). The AC 
manipulates components of the cellular secretory process including the endoplasmic 
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reticulum, Golgi complex and the endosomal machinery. The viral envelope and tegument 
is acquired in the AC, and mature virions or dense bodies are released in the extracellular 








Figure 1.3: HCMV Replication 
 
A) Interaction of infectious viral particles with host receptors facilitates entry into the 
cell, delivering capsid and tegument proteins into the cytosol. B) Microtubules 
mediate transport of capsid to the nucleus, where genome is delivered and 
circularized. Tegument proteins regulate host responses and initiate the sequential 
cascade of Immediate Early (IE), Delayed Early (DE) and Late (L) genes. DE genes 
initiate viral DNA replication. C) Late gene expression initiates capsid assembly in 
the nucleus, which egress to the cytosol. Tegument proteins associate with capsids in 
the cytosol and are trafficked to viral assembly complex (AC), which contains 
components of endoplasmic reticulum (ER), Golgi apparatus and endosomal 
machinery. The capsids acquire tegument and viral envelope and bud into 
intracellular vesicles in the AC. D) Both enveloped infectious particles and non-
infectious dense bodies are released. (Modified from Beltran and Cristea, 2014 [54])     
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1.4.5 HCMV Infection and Infectious Disease 
Primary HCMV infection (first infection in life) in immunocompetent individuals 
is mostly unnoticed or characterized by low-grade fever, mononucleosis-like syndrome, 
fatigue and sore throat. Very rare instances of severe clinical symptoms occur due to 
primary HCMV infection in immunocompetent individuals [55-57]. Primary HCMV 
infection is typically, acquired through direct contact with the genitourinary, respiratory 
and upper alimentary tract [58, 59]. Upon infection, the virus is tackled by a robust host 
immune system. However, HCMV is not eliminated, but rather becomes latent for the 
lifetime of the individual. Latency is also asymptomatic with intermittent reactivation [49].  
The challenges with HCMV arise in immunocompromised individuals, e.g., 
transplant recipients, HIV/AIDS patients or if the immune system is immature resulting in 
cases of congenital HCMV infections. These challenges could be due to primary HCMV 
infection in these individuals or reactivation of HCMV from latency or re-infection by 
another strain of HCMV [60]. In this sense, HCMV is an opportunistic pathogen.  
Transplant recipients undergoing hematopoietic stem cell transplant (HSCT) or 
solid-organ transplant (SCT) are under immunosuppressive drug(s) regimen, which makes 
them prone to HCMV complications. HCMV-seropositive (have IgG antibodies against 
CMV specific antigens) donors can transmit virus to recipients, independent of serological 
status of recipient [61].  Additionally, re-activation and re-infection can contribute to 
morbidity and mortality post-transplantation [62]. Pneumonitis, gastrointestinal ulceration, 
hepatitis, retinitis and death are common manifestations of clinical disease due to HCMV 
infection post-transplantation. Moreover, HCMV promotes graft rejection and accelerates 
atherosclerosis in patients who underwent heart or lung transplant [63]. Currently, these 
complications can be controlled via treatment with Ganciclovir [64].  
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AIDS patients are another subset of the population facing HCMV complications 
due to immunodeficiency. HCMV retinitis and other end-organ disease are common 
challenges in these patients [65]. In certain cases, even after controlling HIV viral load and 
CD4 counts, HCMV results in increased mortality in these patients [66]. Combined 
administration of intraocular and systemic Ganciclovir is a therapeutic treatment of choice 
[67]. 
Congenital HCMV infection is defined as infection of the immature fetus due to 
maternal infection via the placenta within two weeks of birth [68]. In developing countries, 
virtually 100% of women entering childbearing age are HCMV seropositive, and these 
women are susceptible to reactivation of latent virus or reinfection with new strain, both of 
which can be transmitted via placenta to the fetus. In developed countries, many antenatal 
women are seronegative for HCMV making them susceptible to HCMV primary infection 
[60, 69, 70]. Symptomatic children have classic features at birth whereas others are 
asymptomatic at birth but develop symptoms upon follow up. Hepatosplenomegaly, 
microcephaly, thrombocytopenic purpura, and sensorineural hearing loss (SNHL) are 
typical features of HCMV infection at birth. Upon follow-up, SNHL and/or 
neurodevelopmental delay appear as symptoms, which continue progressively [71].  
  
 1.4.6 HCMV Prevalence 
Globally, HCMV prevalence is assessed based on serological status and is 
estimated to be 30–100%. In developed countries, e.g., USA, Europe and Australia, HCMV 
occurrence is between 36–76%. In developing countries such as Brazil, sub-Saharan Africa 
and India, seroprevalence reaches almost 100% [72]. The occurrence of HCMV infection 
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and development of related complications (HCMV disease) varies depending on the broad 
groups (discussed earlier in Section 1.4.5) under consideration.  
Transplant recipients can be broadly categorized as – hematopoietic stem cell 
transplant (HSCT) and solid organ transplant (SOT) patients. Among HSCT cases, both 
groups – allogeneic (stem cells derived from human leukocyte antigen (HLA) matched 
donor) and autologous (stem cells from the same individual) recipients develop HCMV 
disease. In the absence of any prophylactic treatment, HCMV incidence varies based on 
factors like type of immunosuppressive regimen, type of transplantation, HCMV 
serological status match between donor and recipient, and any other illnesses. About 30% 
of allogenic HSCT recipients and 5% of autologous HSCT recipients develop HCMV 
disease [62]. Among SOT recipients, the occurrence of HCMV disease is about 18–29% 
in post liver transplants [73], and as high as 70% after kidney transplants [74]. A large 
multicenter study following heart transplant patients found HCMV is the most common 
infecting organism, accounting for 26% of all infections [75].  
Congenital HCMV infection results in a substantial burden of disease globally but 
the most reliable population-based estimates are from the USA. About 28,000 (0.4% - 
0.7%) babies are born each year with congenital HCMV infection; 12.7% are symptomatic 
at birth whereas 13.5% of asymptomatic babies develop symptoms upon follow-up [71, 76, 
77]. A systematic literature review of studies in developing countries (defined by the 
International Monetary Fund) prior to 2013 estimated a HCMV birth prevalence of 0.6–
6%. Maternal seroprevalence was between 84-100%. HCMV-associated sequelae were not 
documented in most cases [78]. Other reviews have estimated similar HCMV birth 
prevalence in developing countries [70, 77, 79] suggesting that the burden of congenital 
HCMV in developing countries is underappreciated and, in fact, highly neglected. These 
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data also question the dogma in the field that children born with congenital HCMV to 
seropositive mothers have normal clinical outcomes.  
In summary, understanding HCMV prevalence highlights the global burden - 
apparent or silent. 
1.5 MODEL SYSTEMS TO STUDY CMV 
CMVs are associated with many animal species and utilized to study natural 
infections. Rodents (mouse, rat, hamster and guinea pig), rabbits, pigs, horses, bovid 
animals and primates (Rhesus macaque and chimpanzees) are examples of animal species 
infected by CMV. Murine CMV (MCMV) has been used to study the susceptibility of mice 
to infection, effect of CMV on embryonic development, infection of the inner ear, ocular 
infections, and cardiac infection. MCMV has also been utilized to assess latency and 
reactivation [80].  
Cavid herpesvirus type 1 or Guinea Pig CMV (GPCMV) is most commonly utilized 
to understand issues related to in utero CMV infections. Guinea pig placental histology is 
much closer to humans than that of mice and GPCMV can cross the placenta (unlike 
MCMV) and lead to fetal infection and disease. This facilitates evaluation of issues such 
as timing of transplacental transmission, contribution of placenta in assisting or averting 
CMV, how maternal immunity affects the outcome of fetal infection and disease 
pathogenesis in newborns [81]. 
The Rat CMV (RCMV) genome has been sequenced [82] and shown to be 
amenable to mutagenesis [83].  RCMV is now becoming a relevant model to study CMV 
associated transplant issues, e.g., accelerated allograft rejection and development of 
vascular diseases [84]. 
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Porcine CMV (PCMV) has recently garnered attention due to the use of pig organ 
grafts in humans (xenotransplantation). PCMV may be reactivated in grafts, leading to 
development of invasive disease. Hence, studies of PCMV susceptibility to antiviral drugs 
to prevent transmission in pig xenograft organs are valuable and need to be explored in this 
model system [85]. 
Chimpanzee CMV (CCMV) has the most homology to HCMV [86]. However, 
chimpanzees are a protected species and not readily available, making their use limited as 
an animal model system. The other non-human primate model is Rhesus macaque (RM), 
which harbors Rhesus CMV (RhCMV) and is more readily available as a significant model 
system. Rhesus macaques are typically used to evaluate the effect of antivirals in the 
context of bioavailability and toxicity because they are much closer to humans than small 
animal models. RhCMV is also utilized to characterize immune responses in RM. Since 
HCMV is an opportunistic disease in AIDS patients, RMs are also useful to evaluate 
RhCMV disease progression in Simian immunodeficiency virus (SIV)-infected monkeys 
[87].  
Rodents are easier to maintain than larger animals. In addition, inbred mouse strains 
allow minimal individual variation. Strain specific differences in susceptibility of mice to 
MCMV infection [88] have helped dissect out intricate immune mechanisms. Therefore, 
MCMV has been used extensively to understand the biology of CMV and evaluate host 
factors involved in virus replication. Over past decades, significant characterization of viral 
genes involved in MCMV replication and immune responses by the host has been achieved. 
In comparison, there is relatively less understanding of RCMV or GPCMV. Additionally, 
the advent of genetic manipulation tools like CRISPR/Cas9 has improved evaluation of 
host factors in mice [89]. HCMV and MCMV share the type of pathology seen as well as 
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the cells and organs that are infected [88]. However, having described all the advantages 
of the mouse model, it is important to mention that MCMV does not cross the placental 
barrier, limiting [90] its use for studies relating to transplacental transmission of CMV.  
In recent years, advancements in development of humanized mouse models by 
transfer of xenografts have been used to evaluate HCMV [91]. Yet, there are limitations to 
this system and so MCMV continues to be an important small animal model system to 
study CMV biology.   
1.6 MURINE CYTOMEGALOVIRUS (MCMV) 
MCMV belongs to the family of beta herpesviruses and is a large double-stranded 
DNA virus with host specificity for mice. Most of the HCMV structural (described in 
Section 1.4.3 earlier) features are shared with MCMV, including an outer lipid envelope, 
amorphous tegument and icosahedral nucleocapisd. Similar general mechanisms of the 
HCMV and MCMV replication cycles involving a temporally regulated cascade of viral 
genes are also common (described earlier in Section 1.4.4). The genome of HCMV and 
MCMV are both colinear, and many of MCMV proteins share sequence and functional 
similarity with HCMV. This offers advantages for investigation of the contribution of 
conserved genes in the context of the natural host. There are 43 core genes evolutionarily 
conserved among the subfamilies of herpesviruses. Many of these core genes are located 
in the central region of the genome and play a role in basic virus replication [3]. However, 
some core genes are relatively uncharacterized. Our focus is on one such MCMV core 
gene, M72, designated as a 2'deoxyuridine 5'triphosphate pyrophosphatase (dUTPase) 
homolog.   
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1.7 HERPESVIRAL dUTPASE HOMOLOGS 
1.7.1 Cellular dUTPase 
The 2'deoxyuridine 5'triphosphate pyrophosphatase (dUTPase) cellular enzyme is 
involved in conversion of dUTP to dUMP and pyrophosphatase (Fig. 1.3) thus decreasing 
dUTP levels in the host cell. This is important for reducing misincorporation of uracil into 
DNA because most DNA polymerases cannot distinguish between thymine and uracil. In 
addition, the product dUMP is a substrate for thymidylate synthase enzyme and provides 
dTTP precursor for the host cell [92, 93]. Given its significant role in cellular nucleotide 
metabolism, dUTPases are ubiquitous enzymes present in prokaryotes, eukaryotes and 
viruses [94]. Such enzymes are developmentally regulated with high activity in 
undifferentiated cells and low level of activity in terminally differentiated cells. The 
dUTPase expression also varies according to the cell cycle and its levels are elevated in 
dividing cells and reduced in non-dividing cells [95, 96]. 
The dUTPase protein consists of five domains designated as Motifs 1–5. The 
dUTPase fold is a classic jellyroll β-sheet, which forms a homotrimer. The enzyme in most 
organisms is specific for dUTP as a substrate and not dUDP [94]. Human cells have two 
isoforms – nuclear and mitochondrial dUTPases. The nuclear isoform is under cell cycle 
control, whereas the mitochondrial isoform is constitutively active. These isoforms are 
made utilizing alternative 5'exons [97]. 




Figure 1.4: Role of Cellular dUTPase enzyme. 
Catalytic activity of dUTPase enzyme and its contribution to cellular nucleotide pool [93].  
1.7.2 Viral dUTPase homologs 
Multiple examples of viral dUTPases exist among retroviruses and DNA viruses 
[94]. The dUTPase-encoding gene in non-primate lentiviruses is essential for replication 
in non-dividing cells [98]. Similarly, a feline immunodeficiency virus (FIV) dUTPase 
mutant displays a reduced viral burden in vivo, suggesting a contribution to infection in the 
natural host [99]. A dUTPase-homolog is present among all three herpesvirus subfamilies 
- alpha, beta and gamma (summarized in Table 1.4). Among these, alpha and gamma 
herpesvirus dUTPases are enzymatically active [100].  
The Alpha herpesvirus dUTPase is catalytically active but multiple roles 
independent of its enzyme activity have been described. An initial study showed that an 
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HSV 1 dUTPase, UL50, null mutant grows to comparable levels as wild type virus [101]. 
A subsequent study found that an HSV 1 dUTPase mutant is less neurovirulent and exhibits 
diminished capacity to reactivate from latency [102]. Pseudorabies virus (PRV) dUTPase 
UL50 was shown to degrade type I interferon receptor by the lysosomal turnover pathway. 
This activity was independent of dUTPase activity of UL50 [103]. The VZV dUTPase, 
encoded by ORF8, showed a modestly diminished yield in cell culture [104]. The Simian 
varicella virus (SVV) dUTPase encoded also by ORF8, grows to almost comparable levels 
as wild type virus in cell culture and is expressed in the natural host [105]. Among beta 
herpesviruses, examination of the HCMV designated dUTPase homolog, UL72, revealed 
that the protein is catalytically inactive and dispensable for replication in cell culture [106].  
Among gamma herpesviruses, where the designated dUTPase gene product is 
enzymatically active, functions independent of their dUTPase activity are documented. 
EBV encoded dUTPase, BLLF3, contributes to activation of nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-ĸB) [107] and promotes the release of pro-
inflammatory cytokines in a Toll-like Receptor (TLR) 2-dependent fashion [108]. KSHV 
ORF54 reduces the expression of a cell-surface ligand, NKp44L [109]. The Murid 
herpesvirus-68 (MHV-68) dUTPase ORF54 degrades Interferon receptor 1 protein [110]. 
It was established that HSV 2, HHV 6A, HHV 8 and VZV encoded dUTPases contribute 
to cytokine activation and modulate dendritic cell activity utilizing in vitro assays [111]. 
Therefore herpesvirus dUTPase homologs have diverse and significant roles in virus 
biology (Table 1.4). A lack of understanding about the contribution of beta herpesvirus 
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 Table 1.3: Human Herpesvirus dUTPase homologs.  
Summary of dUTPase homologs in Human Herpesviruses (Adapted from M. Williams et 
al., 2017 [112]).  
Virus 
Subfamily 






In vitro  
replication 
Function 
alpha HHV 1/2 
(HSV 1/2) 
UL50 yes no Induces cytokines and 
modulates function of 
dendritic cell (DC) 
alpha HHV 3 
(VZV) 
ORF8 yes no Induces cytokines and 
modulates function of 
DC 
beta HHV 5 
(HCMV) 
UL72 no no ND 
beta HHV 6A  U45 Not 
determined 
(ND) 
ND Induces cytokines and 
modulates function of 
DC 
Beta  HHV 6B U45 ND ND ND 
beta HHV 7 U45 ND ND ND 
gamma HHV 
4(EBV) 




ORF54 yes ND NKp44L suppression 
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1.8  HOST FACTORS NOVEL FOR CMV BIOLOGY 
1.8.1 TRiC/CCT Chaperonin complex 
The eukaryotic chaperonin tailless complex protein -1 (TCP-1) ring complex 
(TRiC)/chaperonin containing tailless complex polypeptide 1 (CCT) referred here as 
TRiC/CCT is a hetero-oligomeric complex implicated in protein folding in the cell. 
1.8.1.1 The Molecular Chaperone System  
Chaperones and chaperonins are sub-classes of a distinct family of proteins 
commonly termed molecular chaperones that are involved in folding polypeptides in the 
cell but are not components of the structures formed [113]. Chaperones are monomeric, 
70–90 kilo dalton (kDa) proteins and strikingly stress-inducible. Some commonly studied 
examples are the Hsp70 and Hsp90 family of proteins. They include the bacterial proteins 
DnaK, DnaJ and GrpE; eukaryotic cytosolic protein Hsp72, mHsp70 from mitochondria 
and BiP in the endoplasmic reticulum as representative examples [114]. In contrast, 
chaperonins are oligomers of approximately 800 kDa molecular weight that have multiple 
subunits and are stress-independent. The bacterial GroEL/GroES system and the 
eukaryotic TRiC/CCT family belong to this sub-class [115].  
1.8.1.2 Features of the TRiC/CCT Chaperonin complex 
The TRiC/CCT chaperonin is composed of eight paralogous subunits (CCT 1-8) 
arranged as back-to-back double-rings surrounding a central cavity. The yeast subunits are 
called CCT (1-8) p whereas, in mammalian cells they are referred to as CCT α, β, γ, δ, ε, 
ζ, η and θ [116]. A ninth testis specific subunit has been described with homology to CCT 
ζ and referred as CCT ζ-2 [117]. The eight different subunits are made from eight 
homologous genes [116]. This complex operates in an ATP-dependent manner with cycles 
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of conformational changes upon nucleotide binding and hydrolysis that aid opening of the 
chamber and encapsulation of the substrate [118, 119]. A specific arrangement of the eight 
subunits surround the ring [120, 121]. Each subunit has an apical, intermediate and 
equatorial domain. The equatorial domain has nucleotide-binding capacity whereas the 
apical domain is involved in substrate specificity. The flexible intermediate domain 
connects the two. The apical domain is diverse in terms of its sequence compared to the 
equatorial and intermediate domains. This suggests that the eight subunits capture a wide 
variety of client proteins within the ring [122-124]. CCT is not upregulated during heat 
shock, indicating a contribution to protein folding in a normal cellular environment [125]. 
1.8.1.3 Principles of TRiC/CCT Chaperonin complex substrate recognition 
The substrate specificity of TRiC/CCT is complex and not well understood. 
Simpler rules regarding hydrophobicity and sequence features of proteins are not sufficient 
to explain substrate recognition mechanisms. A combination of in vivo screening and 
bioinformatics approaches estimated that approximately 6-7% of the eukaryotic cellular 
proteome is a substrate of the TRiC/CCT complex [126]. Although previous reports had 
suggested a TRiC/CCT binding sequence motif [127, 128], later analysis failed to identify 
any consensus sequence common between the identified substrate proteins. Instead, 
structural features, such as proteins prone to be part of oligomer assembly or proteins with 
a propensity for β-sheets (and low α helical content) for 35-45 amino acid stretches, were 
common in substrate proteins. These features along with co-translational association and 
association with co-chaperone proteins contribute to substrate binding[126]. Additionally, 
in lieu of single substrate-apical domain interaction, binding with multiple subunits at 
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discrete sites offers a more stable interaction with substrate. Thus, TRiC/CCT interacts 
with more diverse sets of proteins compared to GroEL chaperonin in bacteria [129]. 
1.8.1.4 Host proteins as substrates of the TRiC/CCT Chaperonin complex 
Actin and tubulin are two well-characterized substrates of the TRiC/CCT complex 
[130, 131]. Other examples include the heavy meromyosin (HMM) fragment of skeletal 
muscle myosin, which complexes with TRiC/CCT in a rabbit reticulocyte lysate (RRL) 
system [132]. Additionally, some cell-cycle related proteins have been identified as 
TRiC/CCT substrates. Cyclin E, involved in G1/S phase transition utilizes TRiC/CCT 
complex to achieve its native structure [133]. Polo-like kinase 1 is a protein, which 
participates in G2/M cell cycle progression and associates with TRiC/CCT immediately 
after translation. Transient knockdown of TRiC/CCT α resulted in G2 mitotic arrest [134]. 
Cdc20 is responsible for Anaphase promoting complex or cyclosome (APC/C) activation 
during metaphase to anaphase transition. Cdh1 is important for maintaining the APC/C 
during exit from mitosis into G1. Both Cdc20 and Cdh1 belong to a class of proteins 
referred as WD repeat proteins [a conserved 40 amino acid core ending with tryptophan-
aspartic acid (WD)] [135], which use TRiC/CCT for protein folding. Cdc20 and Cdh1 are 
TRiC/CCT substrates [136]. Subsequently, upon folding, Cdc20 and Cdh1 may utilize 
TRiC/CCT as a platform to further assemble into a functional complex with APC/C [120]. 
The von Hippel-Lindau (VHL) tumor suppressor protein involved in renal clear cell 
carcinoma is a similar example of TriC/CCT substrate, which upon folding utilizes the 
chaperonin as a platform for assembly into a functional complex with elongin B and 
elongin C [137, 138].  
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1.8.1.5 Viral proteins as substrates of TRiC/CCT Chaperonin complex  
Multiple viral proteins use the TRiC/CCT complex. Rabies nucleoprotein N and 
phosphoprotein P recruit the chaperonin γ subunit to Negri bodies (inclusion bodies) in 
mouse neuronal cells. Knockdown of the TRiC/CCT γ subunit results in reduced Rabies 
virus replication level [139]. Hepatitis C virus (HCV) non-structural protein NS5B, the 
viral RNA polymerase, interacts with the TRiC/CCT ε (CCT 5) subunit. Upon silencing of 
TRiC/CCT ε, a decrease in viral RNA is observed. The suggested mechanism is that 
TRiC/CCT potentially is recruited to the replication complex to aid in folding the 
components involved [140]. Hepatitis B virus capsid protein, a homomultimer, associates 
with TRiC/CCT 1 protein in the form of an assembly intermediate in a cell-free system. 
This interaction does not occur with the initial unassembled polypeptide or the ultimate 
capsid product [141]. The Gag polyprotein of Mason-Pfizer monkey virus (M-PMV) a type 
D retrovirus, associates with TRiC/CCT γ subunit in an ATP-dependent manner, 
suggesting that the chaperonin complex is involved in capsid assembly [142]. Recent 
reports also show that Reovirus capsid protein σ3 utilizes the TRiC/CCT complex for its 
assembly. The chaperonin may retain aggregation-prone regions of the σ3 protein, similar 
to the VHL tumor suppressor protein discussed earlier, preparing it for assembly [143]. 
Interestingly, a previous example of a TRiC/CCT interaction has been reported for the 
herpesvirus family. EBV nuclear protein 3 (EBNA-3) interacts with the ε subunit of the 
eukaryotic chaperonin complex [144], but the significance of this interaction remains 
uncharacterized.  
The above examples suggest that diverse proteins, including viral proteins, fold and 
assemble via the TRiC/CCT complex. EBV protein provides precedence for the interaction 
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of eukaryotic chaperonins with herpesvirus proteins but also warrants further investigation 
into their role in virus biology. 
1.8.2 CCR4-NOT Transcription complex 
1.8.2.1 Composition of the CCR4-NOT complex 
Carbon catabolite repression 4 (CCR4)-negative on TATA-less (NOT) or CCR4-
NOT transcription complex is a large complex with eight core subunits in mammalian cells 
and nine subunits in yeast. The core CCR4-NOT complex is highly conserved across 
eukaryotes [145, 146] and is present in flies, worms, yeast, mice, humans and plants. The 
yeast was utilized extensively to characterize the complex initially; however, in recent 
years more work has focused on mammalian cells. Yeast core complex has five NOT 
subunits and two catalytic modules Caf1 (Pop2) and CCR4. The human complex consists 
of CNOT1, CNOT2, CNOT3, CNOT4, CNOT6/6L, and CNOT7/8 and CNOT9 subunits 
(summarized in Table 1.4) [147, 148]. Some additional subunits identified in the human 
CCR4-NOT complex via co-immunoprecipitation and mass spectrometry approaches 
include CNOT10, CNOT11 (C2ORF29) and the 182-kDa Tankyrase binding protein 
(TAB182) [147, 149, 150].  
The association for some of the additional components varies. For example, 
association of CNOT4 has been suggested to be a regulated event. TAB182 does not co-
immunoprecipitate under all conditions with the CCR4-NOT complex ([147, 149, 150]. 
Differences in the composition of the complex also have been suggested from variation in 
the deadenylase subunits (CNOT6, CNOT6L, CNOT7 and CNOT8) associated with the 
complex [151]. Additionally, there is evidence for tissue specific expression of different 
subunits [152]. The multiple subunits of the CCR4-NOT complex exhibit diverse 
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subcellular localization and are present in both the nucleus and cytoplasm (summarized in 
Fig. 1.5). TAB182 is often reported to be abundantly co-immunoprecipitated with the 
CCR4-NOT complex [149], and yet suggested to be associated in certain conditions [150]. 





Sc (Yeast) Mm (Mouse) Hs (Human)  Protein Domains 
Not1 CNOT1 CNOT1  
Not2 CNOT2 CNOT2  
Not3 CNOT3 CNOT3  
Not4 CNOT4 CNOT4 RING E3 Ligase 
Not5    
Ccr4 CCR4 CNOT6 EEP, LRR 
 CCR4L/CNOT6L CNOT6L EEP, LRR 
Pop2/Caf1 CNOT7 CNOT7 DEDD 
 CNOT8 CNOT8 DEDD 
Caf40  CNOT9  
Caf130  CNOT10  
Dhh1 Rck/p54/DDX6 Rck/p54/DDX6 DEAD-box 
Table 1.4: Homologues and Orthologues of the CCR4-NOT complex. 
The above table summarizes orthologues of CCR4-NOT complex subunits across 
Sacccharomyces cerevisiae (Sc), Mus musculus (Mm) and Homo sapiens (Hs). Protein 
domains present in subunits like exonuclease-endonuclease-phosphatase (EEP), Leucine 
rich repeat (LRR), Asp-Glu-Asp-Asp (DEDD) and Asp-Glu-Ala-Asp (DEAD) box 
helicase family are shown (Adapted from Jason Miller et al., 2012 [148]).  
 
1. Yeast Not5 has no clear homologue in Ms and Hs but there is similarity with CNOT3 
module in Mm and Hs.  
2. Yeast CCr4 has diverged to CNOT6 and CNOT6L.  







Figure 1.5: Subcellular localization of components of CCR4-NOT transcription 
complex in metazoans. 
 
Human (Hs) CNOT2 and Murine (Mm) CNOT9 are mainly localized in the nucleus. Hs 
CNOT6, Hs CNOT6L and Mm CNOT8 are primarily present in the cytoplasm. CNOT1, 
3, 6, 7 and 9 are present in P-bodies (cytoplasmic structures known to contain 
translationally repressed factors and mRNAs). CNOT7 is present in the nucleus and 




1.8.2.2 Diverse roles of the CCR4-NOT complex 
The CCR4-NOT transcription complex plays an important role in multiple 
processes (summarized in Fig. 1.5), and has been reviewed extensively [153-155] 
especially from the context of yeast system. Here I will focus on roles in mammalian cells 
particularly for some of the CNOT subunits relevant to this dissertation. Cell proliferation, 
transcriptional regulation, protein modification and deadenylation (removal of polyA 
residues) of mRNAs are some well-studied functions of this complex.  
CNOT1 is the largest subunit and is involved in structural assembly of this complex 
[154]. This subunit has no catalytic activity by itself but its depletion negatively affects the 
deadenylase activity in HeLa cells and reduces the number of processing bodies or P-bodies 
(cytoplasmic structures involved in mRNA turnover) [156]. Additionally, CNOT1 interacts 
with specific RNA-binding proteins and determines the mRNA target specificity for 
deadenylase activity. This is exemplified by Tristetraprolin, an RNA-binding protein which 
reduces gene expression of AU-rich target mRNAs by interacting with the CNOT1 [157]. 
In addition, Nanos 1-3 paralogs are RNA-binding proteins, which utilize CNOT1 
interaction to diminish target mRNA expression [158].  
CNOT2 and CNOT3 have a conserved NOT-box at their carboxyl terminus and in 
this sense are structurally similar [159]. They do not possess enzymatic activities, but 
potentially contribute to deadenylase activity since CNOT2 depletion reduces deadenylase 
activity in cultured human cells [156]. CNOT2 regulates breast cancer metastasis in a 




CNOT4 possess RING-finger ubiquitin E3 ligase activity and showed in vitro 
ubiquitination activity. This subunit has been implicated in posttranslational regulation and 
protein turnover functions mediated via interaction with several accessory proteins [162].  
CNOT6, CNOT6L, CNOT7 and CNOT8 are associated with deadenylase activities. 
Both human and mouse CNOT6 and CNOT6L possess an amino-terminal leucine-rich 
repeat (LRR) domain and a carboxyl-terminal endonuclease-exonuclease-phosphatase 
(EEP) domain [163]. Human CNOT6 and CNOT6L are paralogs and mutually exclusive 
in co-immunoprecipitation experiments using HeLa cells, suggesting that they have 
redundant functions [151]. CNOT6 is expressed in spleen, thymus, ovary and testis. In 
contrast, CNOT6L is ubiquitously expressed in different tissues [152]. Human CNOT6L 
contributes to cell proliferation by decreasing p27/kip mRNA level in MCF7 cells [164]. 
Additionally CNOT6L, and not CNOT6, depletion contributes to cell proliferation in 
NIH3T3 cells [165].   
Knockout mice are generally embryonically lethal for distinct subunits of this 
complex. CNOT1, CNOT3, CNOT9 and CNOT10 knockout mice have an embryonically 
lethal phenotype (unpublished account in [154]), suggesting roles in embryogenesis. 
CNOT 7 knockout mice are deficient in spermatogenesis [166] and exhibit a high bone 
mass phenotype[167]. Together these data suggest that the CCR4-NOT complex has a 




   
Figure 1.6: Diverse roles of the CCR4-NOT transcription complex. 
 
The above figure summarizes role of components of CCR4-NOT complex in mRNA 






The 182-kDa Tankyrase binding protein (TAB182) or Tankyrase 1 binding protein 
1 (TNKS1BP1) was first identified in a yeast-two hybrid screen as an interacting partner 
and novel acceptor of Tankyrase 1 [168]. Tankyrase 1 or PARP5a is a member of the poly 
adenosine diphosphate (ADP) polymerase (PARP) superfamily and can modify proteins 
post-translationally by addition of single ADP molecules or their polymers [169, 170]. 
Tankyrase 1, which has a complex subcellular localization pattern and is present in both 
nucleus and cytoplasm, modifies TAB182 in vitro [168]. However, little is known about 
its biology.  
A large-scale screen found that TAB182 is highly phosphorylated upon exposure 
to ionizing radiation [171]. TAB182 facilitates DNA double-strand break repair by aiding 
DNA-dependent protein kinase catalytic subunit (DNA-PKc) autophosphorylation in a 
PARP 1 dependent manner. DNA dependent protein kinase complex is an important 
component of non- homologous end joining (NHEJ) pathway [172]. TAB182 expression 
is elevated in lung adenocarcinoma tissue. Depletion of TAB182 in lung cancer cells 
affected its sensitivity to multiple DNA damage agents. In addition, disruption of TAB182 
affected the homologous recombination (HR) pathway as evidenced by disruption of 
RAD51 foci formation [173]. Thus, the available reports suggest a role for TAB182 in the 
DNA damage response, though the mechanism is not clear. TAB182 additionally 
contributes to actin cytoskeleton rearrangement and cancer cell invasion [174]. 
In the context of the CCR4-NOT transcription complex, initially TAB182 was 
suggested as a species-specific component of the human complex based on co-
immunoprecipitation experiments. TAB182 was not associated with the yeast complex 
[151]. Subsequently, numerous large-scale human protein interactome screens identified 
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association of TAB182 with CCR4-NOT complex subunits [175-177]. Although an earlier 
report suggested that TAB182 associates with CCR4-NOT complex only in certain 
conditions [150], a recent report argued that TAB182 is an integral component of the 
CCR4-NOT complex in human cells. CNOT4 was not detected in TAB182 co-
immunoprecipitates, but CNOT 7 and CNOT8 were observed sporadically [178]. Thus 
TAB182 association with the CCR4-NOT complex might be variable depending on 
whether other CCR4-NOT complex subunits are associated. Tankyrase-1 interaction with 
TAB182, as a member of CCR4-NOT complex, is unknown. In addition, the function of 
TAB182 in the context of association with CCR4-NOT complex can be described best as 
emerging. Hence, the association of TAB182 as a component of the CCR4-NOT complex 
and its biology must be evaluated in a very specific context.  
1.8.2.4 Interplay between viruses and components of CCR4-NOT transcription 
complex  
Limited examples of viruses associated with constituents of CCR4-NOT complex 
and TAB182 have been described. Human Papillomavirus, a small DNA tumor virus, 
encodes the E6 protein, which is a major driver of tumorigenesis. A protein interaction 
screen (immunoprecipitation followed by LC-MS/MS) designed to identify protein-protein 
interactions of 16 different E6 proteins with host factors was able to identify CNOT1, 
CNOT2, CNOT3, CNOT4, CNOT6L, CNOT7, CNOT9, CNOT10, CNOT11 and TAB182 
as high confidence host candidates interacting with HPV17a and HPV38 E6 proteins. 
Subsequently, this report validated E6 protein from HPV17a and HPV38 co-
immunoprecipitates with CNOT1, CNOT2 and CNOT3 subunits. Downstream effects of 
this interaction are not well understood [179]. A genome-wide siRNA screen identified 
CNOT1, CNOT2, CNOT3 and CNOT6L subunits required for Hepatitis C virus 
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(Flaviviridae; RNA virus) replication and its mechanistic significance awaits further 
investigation [180]. In an attempt to identify E3 ligases contributing to Influenza A virus 
(IAV) replication, CNOT4, a RING E3 ligase, was identified as a host factor. Knockdown 
of CNOT4 diminished IAV replication. CNOT4 ubiquitinates IAV nucleoprotein (NP) and 
enhances viral replication. NP is the most abundant IAV protein and participates in viral 
RNA transcription and replication. Ubiquitination of NP CNOT4 does not lead to 
degradation of IAV nucleoprotein, suggesting that protein modifications contribute to the 
structure and function of nucleoprotein [181]. TAB182 along with CNOT3 and CNOT7 is 
degraded upon adenovirus serotype 5 and 12 infection. Degradation is dependent on 
adenovirus E1B55K and E4orf6 proteins. Depletion of TAB182 and CNOT1 promotes 
adenovirus replication via increased expression of E1A mRNA expression. Subsequent 
mechanisms need to be investigated further but suggests that TAB182 and CNOT1 control 
adenovirus replication [178]. Components of CCR4-NOT are thus involved in diverse 
ways with viral infection.   
1.9 SUMMARY: OUTLINE OF THIS DISSERTATION 
Through the introductory Chapter 1, I have highlighted the diversity of the family 
of herpesviruses and disease associations, the significance of HCMV mortality and 
morbidity, and the role of multiple small animal models to investigate HCMV. Owing to 
advantages associated with MCMV, I have used mice as my small animal model of choice 
during my dissertation research to investigate M72, a core beta herpesvirus gene. This gene 
was designated as a dUTPase homolog, which has examples in other members of the 
herpesvirus family with diverse functions. Little is known about the dUTPase homologs in 
the beta herpesvirus subfamily. I showed that MCMV M72 is non-functional as a dUTPase. 
41 
 
In Chapter 2, I demonstrated M72’s contribution to virus replication in cell culture and 
the natural host.  
To begin to understand the function of M72, I identified TRiC/CCT chaperonin 
complex and components of the CCR4-NOT transcription complex as interacting partners. 
In Chapter 1, I reviewed these host factors, novel for herpesviruses. In Chapter 2, I 
elaborated on the nature of MCMV M72 and TRiC/CCT interaction. In Chapter 3, I 
focused on the interaction and implication of components of CCR4-NOT transcription 
complex on MCMV M72. In Chapter 4, I described my overall conclusions, future 




Chapter 2:  Murine cytomegalovirus M72 promotes acute virus 
replication in vivo and is a substrate of the TRiC/CCT complex2 
2.1 INTRODUCTION 
Human cytomegalovirus (HCMV), a betaherpesvirus, is the major infectious cause 
of birth defects in developed countries [182]. It has the potential to cause permanent 
neurological damage including microcephaly, cognitive impairment and sensorineural 
hearing loss in CMV-infected newborns [183]. Owing to the high cost of caring for children 
with congenital infections, HCMV has been prioritized as a candidate for vaccine 
development in the United States [184]. Immunocompromised individuals, including 
transplant recipients and HIV-infected persons, represent another susceptible population in 
which HCMV represents a major cause of morbidity and mortality. In this group, problems 
arise due to acute infection or reactivation, including retinitis, hepatitis, and pneumonitis 
[185, 186]. 
The narrow host range of HCMV presents a challenging for study of the role of 
viral genes in the context of the natural host. Hence, MCMV infections of mice are used 
as a tractable animal model for studies of CMV pathogenesis. Sequence and functional 
homologs of viral genes among the CMVs of different hosts facilitate studies of specific 
pathogenic mechanisms [187, 188]. MCMV has a wide variety of genes that contribute to 
                                               
2Large portions of this chapter are part of the paper [1]. Ibid.. 
Briefly, following authors contributed to the paper – Sandhya Gopal (SG), Encarnacion Perez Jr. (EP), 
Amanda Y. Xia (AX), Jonathan J. Knowlton (JK), Filipe Cerqueira (FC), Terence S. Dermody (TD) and 
Jason W. Upton (JWU). SG and JWU designed the experiments. SG, EP, AX, JK, FC, JWU performed the 
experiments. SG wrote the manuscript and primarily JWU edited it. TD, JK, EP and FC provided additional 
input in manuscript writing.   
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its ability to infect and evade the host responses. This leads to the establishment of an 
intricate life-long host pathogen relationship, characteristic of all herpesviruses. The gamut 
of MCMV genes includes a subset of core genes that are evolutionarily conserved across 
herpesviruses. Most of these genes encode proteins required for replication and virus 
structure. However, many core genes remain relatively uncharacterized, and little is known 
about their contribution to infection. The MCMV gene, M72, designated as a 2' 
deoxyuridine 5'triphosphate pyrophosphatase (dUTPase) homolog, is one such example of 
a core gene with no identified function [189].  
Cellular dUTPases are ubiquitous enzymes that convert dUTP to dUMP and 
pyrophosphate (PPi) to control cellular nucleotide pools and prevent misincorporation of 
uracil into cellular DNA. There are several examples of viral dUTPases among retroviruses 
and DNA viruses [94]. The dUTPase-encoding gene in non-primate lentiviruses is essential 
for replication in non-dividing cells [98]. Similarly, a feline immunodeficiency virus (FIV) 
dUTPase mutant displays a reduced viral burden in vivo, suggesting a contribution to 
infection in the natural host [99]. Among herpesviruses, a dUTPase-encoding gene is 
present in all three herpesvirus family subdivisions, and the alpha- and gamma-
herpesviruses dUTPases are functional enzymes [100]. The varicella zoster virus (VZV) 
and simian varicella virus (SVV) dUTPases, encoded by ORF8 of each virus, contribute to 
virus replication in cell culture [104, 190].  Additionally, a null mutant for the HSV 1 
dUTPase, UL50, is less virulent compared to wild type virus and exhibits decreased 
neurovirulence [102].  
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Many herpesvirus dUTPases have functions independent of their dUTPase activity. 
KSHV and murid herpesvirus-68 (MHV-68) ORF54 down-regulate a cell-surface ligand, 
NKp44L [109], and degrade IFN receptor 1 protein [110], respectively. EBV dUTPase, 
BLLF3, activates NF-ĸB [107] and induces the secretion of pro-inflammatory cytokines in 
a TLR2-dependent manner [108]. Thus, some are functions associated with alpha- and 
gammaherpesvirus designated dUTPases are independent of their catalytic activity.  
Little is known about the beta herpesvirus dUTPase homologs. Preliminary 
characterization of the HCMV designated dUTPase homolog, UL72, revealed that this 
protein is catalytically inactive and dispensable for replication in cell culture [191]. Here, 
I report that the MCMV designated dUTPase homolog, M72, is also non-functional as a 
dUTPase enzyme, augments virus replication in some cell types, and contributes to viral 
pathogenesis in the acute phase of replication in the natural host. The M72 protein is 
expressed from early times post infection, shows a complex expression profile that includes 
multiple shorter isoforms, and is a substrate of the eukaryotic chaperonin tailless complex 
protein -1 (TCP-1) ring complex (TRiC)/chaperonin containing tailless complex 
polypeptide 1 (CCT). Together, this initial characterization of M72 reveals new insight into 
betaherpesvirus dUTPase homologs and highlights the contribution of M72 to viral 
pathogenesis. 
2.2 RESULTS  
2.2.1 M72 is not an active dUTPase 
MCMV M72 is designated as a dUTPase homolog based on limited sequence 
similarity with other herpesviruses and homology to HCMV UL72 [13]. To determine 
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whether M72 possesses intrinsic dUTPase activity, a previously described approach was 
employed [110]. Briefly, transfected viral dUTPases and homologs were purified from cell 
lysates and incubated with dUTP, where functional dUTPase enzymes convert dUTP to 
dUMP and pyrophosphate. The sample was then used in place of dTTP in PCR, where 
dUTP that has not been enzymatically processed will be incorporated into the amplicon 
and result in a successful reaction. MHV-68 ORF54 and its catalytic mutant, 
ORF54H80A/D85N [110], were used as positive and negative controls, respectively. 
Immunoblots confirmed expression and immunoprecipitation of transfected, epitope 
tagged M72 and ORF54 proteins (Fig. 2.1A). As expected, MHV-68 ORF54 showed 
enzymatic activity as a dUTPase, consuming dUTP in the in vitro reaction. The 
ORF54H80A/D85N catalytic mutant was incapable of depleting provided dUTP, resulting in a 
positive PCR (Fig. 2.1B). In comparison to the controls, both amino- and carboxy-terminal 
epitope tagged M72 did not display dUTPase activity similar to the MHV68 ORF54 
catalytic mutant (Fig. 2.1B). These results suggest that the MCMV M72 gene product is 












Figure 2.1: M72 is not an active dUTPase. 
A) Immunoblot (IB) analysis of immunoprecipitations (IP) and whole cell lysates (WCL) 
from HEK293T cells transfected 24 hr with the indicated expression vector. B) Ethidium 
bromide (EtBr) stained agarose gel of PCR utilizing individual dNTPs, with dTTP replaced 
by dUTP following incubation with IPs from (A). Presence of a PCR product indicates 




2.2.2 Generation of M72 mutant viruses 
To investigate the potential role of M72 in MCMV pathogenesis, the pARK25 
bacterial artificial chromosome (BAC) containing the K181 (Perth) strain of MCMV [192] 
was used to introduce two independent premature stop codons into the M72 open reading 
frame with established recombineering techniques (see in Fig. 2.2A) [192]. Initially, a 
selection/counter selection cassette (sacB/KanR) was inserted into a region including the 
M72 open reading frame (corresponding to the MCMV genome between nucleotide 
102,772–105,791) by allelic exchange. This cassette was replaced in a second allelic 
exchange step with two independent amplicons containing engineered stop codons inserted 
within the M72 gene. The 5'-end of the M72 gene on the complementary strand was 
overlapped by the 5' ends of M73 and M73.5 genes. To prevent disruption of the M73 and 
M73.5, mutations were inserted into a non-overlapping region in the 5' end of M72. The 
BACs were analyzed by restriction fragment length polymorphism (RFLP) and 
PCR/restriction digest to ensure the structural integrity and presence of intended mutations. 
Isolated BAC DNA digested with HindIII or PstI revealed the anticipated patterns due to 
the insertion of the sacB/KanR cassette. The M72.SK BAC digested with HindIII showed 
the appearance of a unique 2,007 bp band, whereas PstI digestion revealed the loss of a 
4,931 bp band and addition of a unique 8,828 bp band. These differences were absent from 
the specific mutant BACs, which were indistinguishable from WT BAC (Fig. 2.2B). As 
expected, amplification of the region around M72 from WT and mutant BACs produced 
amplicons of 2,082 bp, whereas the sacB/KanR containing M72.SK produced an amplicon 
of 4,000bp. Moreover, digestion of amplicons with SpeI or NheI revealed the insertion of 
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specific mutations linked to each unique diagnostic restriction enzyme site in M72StopS 
and M72StopN (Fig. 2.2C), respectively. WT and mutant BAC DNAs were transfected 
into NIH3T3 fibroblasts and viruses were recovered and amplified. No major differences 
in viral immediate-early (m123/IE1), early (m112-113/E1) or late (MCP/M86) proteins 
were seen in NIH3T3 cells infected with WT, M72StopS or M72StopN (Fig. 2.2D), 







Figure 2.2: Generation of M72StopS and M72StopN recombinant viruses. 
A) Schematic diagram of genomic location of M72 and mutagenesis strategy to generate 
M72StopS and M72StopN. Numbers represent MCMV genomic coordinates (GenBank 
Accession number AM886412.1), and abbreviations indicate restriction enzyme sites (Hi, 
HindIII; Ec, EcoRI; Sp, SpeI; Nh, NheI). M72StopS and M72StopN were generated by a 
two-step allelic exchange strategy (see Materials & Methods) inserting, and then replacing, 
a selection/counterselection cassette (SacB/KanR). Nucleotide and amino acids changed 
are indicated in bold, and underlined sequences represent introduced diagnostic restriction 
enzyme sites. Grey bars represent diagnostic PCR amplicons in C). B) RFLP analysis of 
WT, M72.SK, M72StopS and M72StopN BACs. Isolated DNA was digested with the 
indicated enzyme, separated on a 0.6% agarose gel and visualized by EtBr staining. 
Arrowheads indicate specific important DNA fragments addressed in Results. C) 
Infectious virion DNA from the indicated viruses was isolated, and amplicons from the 
M72 locus generated by PCR. Amplicons were digested with the indicated enzyme or left 
uncut. Products were separated on a 1.0% agarose gel and visualized by EtBr staining. D) 
Western blots of MCMV IE1, E1, M86 and β-actin expression from lysates of NIH3T3 




2.2.3 MCMV M72 augments viral replication in cell culture.   
To begin to understand the contribution of M72 to viral replication, the replication 
of M72StopS and M72StopN mutants were characterized in cell culture. In addition to 
murine fibroblasts, I assessed viral growth in endothelial and macrophage cell types, both 
of which are important for CMV infection. Analysis of yields during single-step infection 
(MOI = 5.0 PFU/cell) showed that M72StopS and M72StopN mutants were attenuated by 
nearly 10-fold in murine fibroblasts (Fig. 2.3A) and endothelial cells (Fig. 2.3B) 
compared with WT virus. However, both the M72Stop mutant viruses replicated to 
comparable levels as the WT virus in a macrophage cell line (Fig. 2.3C) and in bone 
marrow derived macrophage (BMDM) primary cells (Fig. 2.3 D). Multi-step infection 
(MOI = 0.05 PFU/cell) revealed similar trends in each of the three cell types; mutant 
viruses produced lower levels than WT virus in NIH3T3 and SVEC4-10 cells (Fig. 
2.3E,F) and similar levels as WT virus in the macrophage cell line (Fig. 2.3G).  Together, 






Figure 2.3: MCMV M72 augments virus replication in cell culture. 
(A to D) Single-step (5.0 PFU/cell) and (E to G) Multi-step (0.05 PFU/cell) growth curves 
in NIH3T3 fibroblasts (A and D), SVEC4-10 endothelial cells (B and E), RAW264.7 
macrophages (C and F), and BMDM primary cells (D) infected with WT, M72StopS or 
M72StopN recombinant viruses. Each data point represents n = 3 to 6 replicates. Error bars 
represent standard deviation.  Statistical analysis at each time point was performed using 
two-way ANOVA analysis with a Tukey’s multiple comparison test. * - p<0.01, ** - 
p<0.001, *** - p<.0001, **** - P<.00001. Color of asterisks denotes the statistical 
difference of each mutant from WT. The 0 hr time point represents the time immediately 




2.2.4 MCMV M72 augments virus replication in the early phase of acute infection in 
the natural host. 
Since M72 plays a role in efficient replication in cell culture, I next sought to 
determine how disruption of M72 affects virus replication in the context of a natural host. 
BALB/cJ mice were infected via intraperitoneal (i.p.) inoculation with 105 PFU of the 
WT, M72StopS or M72StopN viruses, and viral loads in the spleen and salivary glands 
were determined. Compared with the WT virus, M72StopS and M72StopN viruses were 
each attenuated approximately 10-fold in spleens on day 3 post-inoculation (Fig. 2.4A). 
At day 5 post-inoculation, a similar trend was observed in infected spleens, although with 
greater variation in titers, and differences between the loads of WT and M72Stop mutants 
did not reach statistical significance (Fig. 2.4B). Surprisingly, analysis of salivary gland 
titers at day 7 (Fig. 2.4C) and day 14 (Fig. 2.4D) post-inoculation demonstrated that the 
M72Stop mutants were present at similar levels as the WT virus. This finding indicates 
that the capacity of the M72Stop mutant viruses to disseminate in the natural host 
remains unaffected. Together, these data suggest that MCMV M72 contributes to acute 
replication of the virus during the early phase of infection, but is dispensable for 







Figure 2.4: MCMV M72 augments virus replication in the early phase of acute infection 
in the natural host.  
(A to D) Organ titers from BALB/cJ mice infected with 105 PFU of either WT, M72StopS 
or M72StopN viruses. Spleen (A-B) and salivary gland (C-D) were collected at the 
indicated day (d) post infection, and virus titer determined by plaque assay on NIH3T3 
fibroblasts. Each data set for individual virus represents n = 10-15 mice per group. Error 
bars represent standard deviation.  Statistical analysis at each time point was performed 
using two-way ANOVA analysis with a Tukey’s multiple comparison test. *** - p<.0001, 




2.2.5 Generation of tagged virus and evaluation of M72 protein expression. 
Although introduction of premature translational stop codons into the predicted M72 ORF 
affected viral replication both in vitro and in vivo, little is known about the protein 
expression of M72. M72 is encoded in a transcriptionally complex region of the genome, 
and transcripts corresponding to the M72 gene have been detected in infected cells [193-
195]. Moreover, peptides corresponding to M72 sequence have been detected in MCMV 
virions [196]. However, the expression of M72 protein during infection has not been 
reported. Since M72-specific antibodies are not available, I engineered a recombinant virus 
in which a 3X-FLAG epitope tag was appended to the carboxyl-terminus of M72. The 
predicted stop codon of M72 (nucleotides 103,083–103,086) of the K181 BAC was 
replaced with a sacB/KanR cassette via recombineering. In the subsequent step, this cassette 
was replaced with an amplicon containing a 3X-FLAG epitope fused to the carboxyl-
terminal end of M72 to generate MCMV M72.3XFlag (Fig. 2.5A). RFLP analysis (Fig. 
2.5B), PCR amplification and sequencing (Fig. 2.5D) confirmed the presence of the 
inserted sequence, and infectious virus was recovered.  
To quantify the expression of M72 during infection, NIH3T3 fibroblasts were 
infected with M72.3XFlag at an MOI of 5 PFU/cell. Samples were harvested at the time of 
virus addition (t=0) and at various intervals thereafter for immunoblot analyses. Expression 
of a ~46kDa band, consistent with the estimated and observed molecular mass of full 
length, epitope tagged M72 (Fig. 2.1A) was observed as early as 6 hours post infection 
(h.p.i.), reaching peak levels between 24 and 48 h.p.i. (Fig. 2.5C). Expression of 
immediate-early (m123/IE1), early (m112-113/E1) and late (gB/M55) gene products were 
observed as anticipated (Fig. 2.5C). Addition of the CMV DNA polymerase inhibitor 
phosphonoformic acid (PFA) at the time of infection did not interfere with the expression 
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of IE1 or E1, but significantly reduced the expression of the late protein gB (Fig. 2.5C). 
M72 has previously been designated a late gene based on RNA expression [195]. 
Inconsistent with this, M72 protein expression was not adversely affected by the addition 
of PFA, but instead showed enhanced protein expression of faster migrating isoforms of 
M72. Interestingly, additional, faster migrating protein bands were observed over the time 
course of infection. A similar pattern was observed upon detection of exogenously 
expressed FLAG-tagged M72 (Fig. 2.1A, 2.6B, 2.7B), suggesting that the initial 
observation was not an artifact and that multiple M72 protein isoforms accumulate during 
infection. Based on the approximate molecular masses of the faster migrating isoforms, 
and the number and locations of multiple methionine residues in the N-terminus of M72, 
we hypothesized that initiation of M72 protein isoform expression could be happening 
from internal methionine residues. A series of N-terminal truncations were constructed in 
which each methionine between M1 and M140 were used as the initiating methionine for 
the construct (Fig. 2.5E). Immunoblot analysis of NIH3T3 cells transfected with each of 
the amino-terminal truncations were compared to MCMV-M72.3XFLAG infected cells 
analyzed on the same gel.  Virus-infected cells showed the expected pattern of multiple 
M72 protein isoforms (Fig. 2.5F, left panel), and bands in infected cells migrated consistent 
with expression constructs encoding full length M72 (1-401), M72 (46-401), M72 (76-401) and 
M72 (139-401) (Fig. 2.5F, right panel).  Together, these results suggest a complex expression 









Figure 2.5: Expression of M72 protein during MCMV infection.  
A) Schematic diagram of genomic location of M72 and mutagenesis strategy to generate 
M72.3XFlag. Numbers represent MCMV genomic coordinates (GenBank Accession 
number AM886412.1), and abbreviations indicate restriction enzyme sites (Hi, HindIII; 
Ec, EcoRI). M72.3XFlag was generated by a two-step allelic exchange strategy (see 
Materials & Methods) inserting, and then replacing, a selection/counterselection cassette 
(SacB/KanR) with a 3XFLAG epitope tag. B) RFLP analysis of WT, M72.SK.Tag, and 
M72.3XFlag BACs. Isolated DNA was digested with the indicated enzyme, separated on 
a 0.6% agarose gel and visualized by EtBr staining. C) Immunoblot for FLAG, IE1, E1, 
gB and actin from whole cell lysates of NIH3T3 cells infected with (MOI=5.0 PFU/cell) 
MCMV M72.3XFlag virus in the presence or absence of 200 µg/mL PFA. Samples were 
collected at the indicated time points post infection, separated by SDS-PAGE and 
western blot analysis. The 0 hr time point represents the time of addition of virus to the 
dishes. D) Representative results of sequencing and alignment of the M72.3XFlag 
insertion site. Amplicons were generated from viral genomic DNA using primers 
flanking the end of M72. E) Schematic diagram of epitope-tagged M72 N-terminal 
mutants initiating from specific methionine residues within the open reading frame. 
Numbers preceded by “M” denote the amino acid position of the internal methionine for 
initiation of protein expression for each mutant.  Dark Grey box indicates putative 
‘dUTPase’ domain. Light grey box indicates 3XFlag epitope tag. Numbers denote amino 
acid numbers. F) Immunoblot analysis for FLAG and GAPDH of NIH3T3 cells 





2.2.6 Identifying interacting partners of M72.  
To begin to understand the function of M72, I sought to define cellular interacting 
protein partners of M72. M72-3XFlag or control plasmid were transfected into NIH3T3 
fibroblasts. FLAG-immunoprecipitates were prepared, resolved by 10% SDS-PAGE and 
stained. Multiple bands were observed in the M72-3XFLAG sample relative to the vector 
control (Fig. 6A). A region of each lane in which multiple bands were differentially 
enriched, corresponding to approximately 55-70 kDa, were excised from each sample, 
subjected to in-gel tryptic digestion and LC-MS/MS analysis. Peptide sequences were 
compared to the UniProt mouse reference genome, and used to generate an initial list of 
109 total unique proteins, excluding those of low confidence representation, low 
abundance, or those enriched in the control sample. Proteins for which a minimum of 10 
peptide spectral matches in the experimental sample were detected, and those, which 
showed at least a 2-fold enrichment over control samples were, designated candidate 
interacting proteins (Table 2.1).  
Among the candidates meeting these criteria, all eight subunits of the TRiC/CCT 
complex were significantly enriched in M72-containing immunoprecipitates. TRiC/CCT 
is a hetero-oligomeric complex that aids in cellular protein folding and assembly. The 
complex is a eukaryotic chaperonin and has eight paralogous subunits (TRiC/CCT 1-8) 
arranged in a stacked ring-like structure [197]. TRiC/CCT functions in an ATP-
dependent manner and provides a physically defined compartment in which cellular 
protein domains or entire proteins can fold while being sequestered from the cytosol 
[198]. The TRiC/CCT complex interacts with viral proteins such as the EBNA-3 protein 
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of EBV [144], hepatitis C virus NS5B [140], influenza PB2 [199], rabies virus N and P 
proteins [139],  and reovirus σ3 capsid protein [200], indicating that it is an important 













Peptide spectral counts (PSM) Fold 
enrichment Con M72- 
T-complex protein 1 subunit epsilon (Cct5) TCPE_MOUSE 60 2 151 75.5 
T-complex protein 1 subunit eta (Cct7) TCPH_MOUSE 60 2 150 75.0 
tRNA-splicing ligase RtcB homolog RTCB_MOUSE 55 1 39 39.0 
T-complex protein 1 subunit beta (Cct2) TCPB_MOUSE 57 4 149 37.3 
T-complex protein 1 subunit zeta (Cct6a) TCPZ_MOUSE 58 3 110 36.7 
T-complex protein 1 subunit delta (Cct4) TCPD_MOUSE 58 5 144 28.8 
T-complex protein 1 subunit theta (Cct8) TCPQ_MOUSE 60 8 174 21.8 
T-complex protein 1 subunit alpha (Tcp1) TCPA_MOUSE 61 11 142 12.9 
Polymerase I and transcript release factor PTRF_MOUSE 44 2 15 7.5 
T-complex protein 1 subunit gamma (Cct3) TCPG_MOUSE 61 0 169 - 
60S ribosomal protein L4 RL4_MOUSE 61 0 38 - 
CCR4-NOT transcription complex subunit 2 CNOT2_MOUSE 60 0 34 - 
CCR4-NOT transcription complex subunit 6-like CNO6L_MOUSE 63 0 18 - 
Heterogeneous nuclear ribonucleoprotein K B2M1R6_MOUSE 49 0 17 - 
Protein FAM98A FA98A_MOUSE 55 0 14 - 
Nucleolin NUCL_MOUSE 77 0 13 - 
Protein disulfide-isomerase PDIA1_MOUSE 57 0 12 - 
26S protease regulatory subunit 4 PRS4_MOUSE 49 0 11 - 
Isoform 3 of Myelin expression factor 2 MYEF2_MOUSE 63 0 11 - 
Heterogeneous nuclear ribonucleoprotein L G5E924_MOUSE 67 0 10 - 
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2.2.7 M72 associates with and is a substrate of the TRiC/CCT complex. 
To validate the results of the MS experiment, M72-3XFLAG and each of the HA-
tagged CCT 1-8 subunits were transiently co-expressed in HEK293T cells. 
Immunoprecipitation followed by immunoblotting revealed that M72 co-
immunoprecipitated each of the co-transfected subunits of TRiC/CCT complex, except 
CCT5 (Fig. 2.6B). Interestingly, CCT5 was consistently and reproducibly expressed to 
significantly lower levels when co-transfected with M72. Whether this represents an 
artifact of co-expression, or is indicative of an antagonism remains unclear.  Thus, I am 
unable to conclusively confirm the interaction between M72 and CCT5 observed by mass 
spectrometry (Table 1). An irrelevant, comparably sized and epitope- tagged protein, 
Lsm14a, did not co-immunoprecipitate with M72 indicating the interaction was specific. 
Similar findings were made using M72 with an epitope tag appended to the amino- (data 
not shown) terminus, indicating that the epitope tag did not influence the interaction.  
Since the TRiC/CCT complex is an interacting partner with M72 and required for 
homeostatic protein folding of many cellular proteins, such as actin [201], M72 might 
modulate TRiC/CCT complex activity. However, infection of cells with WT, M72StopS, 
or M72StopN viruses showed no discernable differences or changes of expression of 
individual CCT proteins, and actin protein levels remained constant throughout each 
infection condition (data not shown). This finding suggested that M72 does not affect the 
expression or activity of the TRiC/CCT complex during MCMV infection and raises the 
possibility that M72 is a client protein of the TRiC/CCT complex.  
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To determine whether M72 is a substrate of the TRiC/CCT complex, I employed 
a CCT substrate assay [202]. TRiC/CCT substrates should be released from the complex 
in the presence of MgCl2 and ATP, but remain associated when treated with a divalent 
cation chelator, such as EDTA. Thus, to assess the effect of these treatments on M72 
release from isolated TRiC/CCT complex, cell lysates were prepared from M72-
3XFLAG-transfected HEK293T cells, and divided into four equal aliquots. Aliquots were 
incubated with either EDTA, MgCl2 or, MgCl2 with ATP for 40 min at room 
temperature. Samples were then immunoprecipitated with a mixture of anti-CCT1 and 
CCT8 antibodies to isolate TRiC/CCT complexes and their associated substrates and then 
analyzed by SDS-PAGE and immunoblotting. TRiC/CCT substrates should be released 
in the presence of MgCl2 and ATP, but remain associated with the complex when treated 
with a divalent cation chelator, such as EDTA. Immunoblotting for M72 revealed a 
substantial decrease in M72 co-precipitated with TRiC/CCT complexes in the presence of 
MgCl2 and ATP, whereas comparable levels of M72 were observed in mock- and EDTA-
treated samples (Fig. 2.6C). This result confirms the interaction of M72 with the 
TRiC/CCT complex and suggests that M72 is dissociated from the complex in an ATP-
dependent manner.  
 To more directly test whether M72 is a TRiC/CCT substrate, I investigated the 
association of in vitro translated M72 with TRiC/CCT over time in rabbit reticulocyte 
lysates (RRLs). RRLs are a common tool used to identify and characterize TRiC/CCT 
substrates [203, 204], including human β-actin [201] and Reovirus σ3 [200]. Actin (an 
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obligate TRiC/CCT substrate), GFP (which does not require TRiC/CCT to fold) or M72 
were translated in vitro in the presence of  S35-labeled methionine for 5, 10, or 20 min. 
Reactions were resolved on parallel native and SDS-PAGE gels. As anticipated [200], 
newly translated actin was observed in association with a large complex (>750kDa) in 
native gels, corresponding to the actin/TRiC complex [200, 201, 205]. Over the time 
course, a low molecular weight (<60kDa) form of actin accumulated, consistent with the 
release of monomeric actin from TRiC/CCT (Fig. 2.6D). GFP, which is not a TRiC/CCT 
substrate, did not form a high molecular weight complex with TRiC/CCT, and instead 
consistently accumulated in a monomeric state during translation. In comparison, nascent 
M72 migrated in a high-molecular mass complex with TRiC (Fig. 2.6D). However, 
native M72 did not accumulate as a free monomer consistent with its migration on a 
denaturing gel (Fig. 2.6E), but instead showed a diffuse band ranging from approximately 






Figure 2.6: M72 associates with and is a substrate of the TRiC/CCT complex. 
A) Coomassie stained SDS-PAGE gel of FLAG-immunoprecipitates from NIH3T3 
fibroblasts transfected with M72-3XFLAG or empty vector control (Con). White arrow 
indicates M72-3XFLAG. Black arrowhead and boxed region denote region of 
differentially enriched bands excised and further analyzed by LC-MS/MS (Table 1). 
Asterisks indicate additional regions of potential differentially enriched proteins. B) IB 
analysis for HA, FLAG, and actin in IP and WCL from HEK293Ts co-transfected with 
M72-3XFLAG and HA-epitope tagged TRiC/CCT or control as indicated. C) IB analysis 
for CCT7 and FLAG from TRiC/CCT substrate assay. HEK293T cells were transfected 
with M72-3XFLAG, whole cell lysates collected, aliquoted into 4 parts and incubated with 
EDTA, MgCl2 with or without ATP, or mock treated. Aliquots were subjected to IP with a 
mixture of TCP1/CCT1 and CCT8 antibodies, separated on an SDS-PAGE gel and 
immunoblotted with the indicated antibodies. D-E) Native (D) and SDS- (E) PAGE of 35S-
methionine (Met)-labelled green fluorescent protein (GFP), β-actin, and MCMV M72 
translated for the intervals shown in rabbit reticulocyte lysates (RRLs). Green arrow 
indicates GFP, the grey arrow indicates actin, the white arrow indicates M72, and the black 




2.2.8 M72 forms self-associating oligomers in cell culture.  
To determine whether M72 forms an oligomer, expression constructs for full-
length and C-terminal truncations of M72-3XFLAG (Fig 2.7A) were co-transfected with 
GFP-M72 into HEK293T cells. Immunoprecipitation followed by immunoblotting 
revealed that GFP-M72 co-immunoprecipitates with full length M72-3XFLAG, 
suggesting that M72 forms homo-oligomers both in vitro (Fig. 2.6D) and in vivo (Fig. 
2.7B). Binding of M72-3XFLAG to GFP-M72 is relatively comparable upon deletion of 
the C-terminus to amino acid 282, but is markedly diminished for M72 (1-253) and M72 (1-
226).  Although formally possible that the diminished binding upon deletion of aa 226-283 
is due to modest expression, it is worth noting that M72(1-226) and M72(1-253) are expressed 
as well as M72(1-339), M72(1-311), and M72(1-282), yet consistently co-IP less GPF-M72, 
suggesting that the region of M72 encompassing aa 226-283 are important for efficient 
oligomerization. M72(1-199) co-precipitates with GFP-M72 as well as full length M72, but 
this binding is substantially reduced for fragment 1-172 and 1-136, and is completely lost 
for the smallest fragment, 1-107. Together, these results indicate that regions of M72 
from aa 172-199 and aa 226-282 contribute to M72 oligomerization.  
To determine whether the ability of M72 mutants to oligomerize correlates with 
association of M72 with the TRiC/CCT complex,  expression constructs for full-length 
and a subset of C-terminal truncations of M72-3XFLAG (Fig. 2.7A) were co-transfected 
with HA-CCT8 into HEK293T cells. Immunoprecipitation followed by immunoblotting 
confirmed that full length M72-3XFLAG could co-IP with CCT8, and M72 (1-199) could 
co-IP similar amounts of CCT8 as WT (Fig. 2.7C).  It also revealed that M72 (1-311), 
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which showed a higher level of oligomerization (Fig. 2.7B), also precipitated more CCT8 
than WT M72. M72 mutants defective for oligomerization were similarly diminished in 
their capacity to co-IP CCT8.  Together, these data indicate that M72 forms homo-
oligomers (Fig. 2.7B) which correlates with its ability to associate with components of 





Figure 2.7: M72 forms self-associating oligomers in cell culture. 
Schematic diagram of epitope-tagged M72 carboxy-terminal truncation mutants. Dark grey 
box indicates putative ‘dUTPase’ domain. Light grey box indicates 3XFlag epitope tag. 
Numbers denote amino acid numbers. B) IB analysis for FLAG, GFP, and actin in IP and 
WCL from HEK293T cells co-transfected with eGFP-M72 and the indicated 3XFlag-
tagged M72 plasmids. C) IB analysis for FLAG, HA, and actin in IP and WCL from 
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HEK293T cells co-transfected with HA-CCT8 and the indicated 3XFlag-tagged M72 
plasmids. 
2.3 DISCUSSION 
In this study, I provide an initial characterization of the role of MCMV M72 gene 
during infection in vitro and in vivo. Although related to herpesvirus dUTPase enzymes, 
M72 does not possess intrinsic enzymatic activity (Fig. 2.1), and likely plays no direct 
role in supporting nucleotide biogenesis during infection. Genetic disruption unveiled a 
function for M72 in virus replication in fibroblast and endothelial cell lines in culture 
(Figs. 2.2 and 2.3). In addition, M72 promotes acute virus replication in the early stage of 
infection in a natural host (Fig. 2.4A). Interestingly, mutation of M72 had little effect on 
the capacity of MCMV to disseminate to the salivary glands of infected animals (Fig. 
2.4C-D). M72 protein is expressed as early as 6 h.p.i. with increasing levels up to 48 
hours. Additional, faster migrating M72 isoforms are also detected and accumulate 
throughout infection (Fig. 2.5C). M72 associates with, and is a substrate of, the 
eukaryotic TRiC/CCT chaperonin complex (Fig. 2.6). Like other well-characterized 
TRiC/CCT substrates, such as actin [201], M72 forms oligomers or higher-order 
aggregates in vitro and in vivo. This interaction is mediated by a bipartite region of the 
central portion of M72. Although the specific function of M72 during infection remains 
unclear, my results indicate complex viral and host regulation of M72 protein expression 




The dUTPases are classified into three subgroups based on their oligomerization 
states:, monomeric, dimeric and trimeric. Avian and mammalian herpesvirus dUTPase 
enzymes are exclusively monomeric, and bioinformatics analysis suggest that trimeric 
and monomeric dUTPases contain five conserved motifs for catalytic activity [206]. 
Herpesvirus dUTPase homologs also have an additional motif 6 of unknown function 
[94, 100, 206]. MCMV M72 was designated as a dUTPase homolog based on limited 
sequence similarity and positional homology with other herpesvirus dUTPase homologs 
[13]. Among human beta herpesvirus dUTPase homolog, HCMV UL72 and Human 
Herpesvirus 6A (HHV-6A) U45 are catalytically inactive [111, 191]. My results confirm 
that, like other beta herpesvirus dUTPase homologs, M72 is not a functional enzyme 
(Fig. 2.1). Moreover, an examination of the M72 protein sequence shows a loss of the 5 
motifs necessary for enzymatic activity and only has the herpesvirus conserved motif 6 
[100]. Although many other herpesvirus dUTPase homologs also fulfill enzyme-
independent roles [107-110], my results indicate that M72 plays an exclusively alternate 
role during infection. 
Previous functional profiling studies of the entire HCMV genome indicated that 
HCMV UL72 is non-essential for replication [207, 208], and a clean UL72 deletion 
mutant [191] has a modest replication defect in cell culture. My examination of MCMV 
M72 mutant infection revealed that M72 contributes to virus replication in murine 
fibroblasts and endothelial cells, similar to the results for HCMV UL72. These results are 
consistent at both high and low multiplicities of infection (Fig. 2.3 A, B, E, F)), 
73 
 
suggesting that the defect is MOI-independent. However, I also observed that M72 
mutant viruses produced yields comparable to or even higher than WT MCMV in murine 
macrophage cell lines (Fig. 2.3 C and G) and BMDMs (Fig. 2.3 D). This result may be 
indicative of a tissue-specific contribution of M72 during viral infection.  
In the context of a natural host, the MHV-68 dUTPase, ORF54, is required for 
establishment of latency, but dispensable for acute replication in lungs of infected mice 
[110]. Additionally, pseudorabies virus lacking its dUTPase homolog, UL50, is also 
attenuated for virulence and replication in infected swine [15]. However, there are no 
reports of the contribution of beta herpesvirus dUTPase homologs to infection in the 
natural host. I show here that M72 augments virus replication during acute replication in 
spleen at early times post infection (Fig. 2.4). Interestingly, M72Stop mutants effectively 
disseminated to the salivary glands of infected animals, similar to WT virus (Fig. 2.4C-
D). Thus, despite early acute defects in replication seen in vivo (Fig. 2.4A), M72-
deficient viruses can infect and replicate in the disseminating cell population, showing no 
defects at later times post infection.  Mononuclear phagocytes are the main cell type that 
contributes to dissemination of MCMV [209], likely after acquiring virus from 
susceptible cells at sites of primary infection. This result is consistent with my findings in 
cell culture where there is a modest defect in viral replication in endothelial cells and 
fibroblasts, but no impairment in the capacity of these viruses to infect and grow in 
macrophage/monocyte cells (Fig. 2.3). Although not an essential gene, M72 appears to 
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alleviate barriers to replication in some types of cells.  Future studies will provide 
insights into the host restriction mechanisms overcome by M72.   
HCMV UL72 and MCMV M72 have been classified as late gene products [191, 
195] based on Northern blot analyses. However, using an epitope-tagged virus, M72 
protein expression was observed as early as 6 h.p.i. and this expression is unaffected by 
addition of PFA (Fig. 2.5C). By comparison, I observed diminished expression of 
glycoprotein B/M55, a late gene, in the presence of PFA, indicating that drug treatment 
was effective. The expression pattern of M72 protein more closely mimics that of the 
m112/3 (E1) protein, a well-known delayed-early gene. Thus, M72 is likely a leaky-late 
gene product, requiring delayed early protein function, but not requiring viral DNA 
replication.  
Another unanticipated result was the observation of faster migrating FLAG-
epitope tagged species by SDS-PAGE analysis from cells infected with MCMV-
M72.3XFlag. A similar expression profile, including the faster migrating bands, was 
observed in infected murine endothelial (SVEC) and macrophage (RAW264.7) cell lines 
(data not shown), suggesting this phenomenon is independent of cell type. An additional 
independent HA-epitope tagged M72 recombinant virus displays similar faster migrating 
bands (data not shown), indicating these bands are not an artifact of the FLAG epitope 
tag. Initial investigations suggest that that these faster migrating M72 protein isoforms 
are similar in size to proteins translated from internal methionine positions within the 
M72 annotated ORF. HCMV UL136 is expressed as multiple protein isoforms and a 
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detailed characterization of the different isoforms using independent recombinant viruses 
revealed novel functions for each [210-212]. These isoforms are produced by a complex 
transcriptional program that uses distinct transcription initiation sites for each isoform 
[211]. The M72-M75 region of the MCMV genome is transcriptionally complex [193, 
195]. However, there do not appear to be distinct transcriptional start sites or alternative 
splicing for the M72 transcript. We also observe multiple M72 proteins isoforms being 
expressed following transfection of plasmids encoding the M72 ORF (Fig. 2.1A, 2.6B, 
2.7B), indicating that this is not a function of viral infection or replication. M72StopS and 
M72StopN mutants would be predicted to interrupt some, but not all of the protein 
isoforms observed by western blot analysis. M72StopS and M72StopN would be 
predicted to terminate translation between the 3rd and 4th methionine within the ORF. 
Thus, the full length and two largest possible isoforms would be interrupted by these 
mutations. However, it is formally possible that additional downstream ORFs remain 
open and could be expressed during infection. However, I show that interruption of M72 
by the –StopS and –StopN mutations are sufficient to impair viral replication in vitro and 
in vivo, indicating that longest isoforms of M72 interrupted by both mutations have 
important functions during infection.  
Previous attempts to identify interacting partners of MCMV proteins using  a 
yeast two-hybrid screen showed that M72 engages multiple other viral proteins [213]. 
Since there are no reports of host factors that interact with M72, I used a proteomics 
approach to identify cellular proteins that bind M72. Identification of such proteins may 
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provide clues to M72 function. I identified and confirmed the interaction of M72 in vitro 
and in vivo with components of the eukaryotic TRiC/CCT complex (Fig. 5). TRiC/CCT 
is a well characterized eukaryotic chaperonin and contributes to protein folding of an 
estimated 5-10% of the cellular proteome [126]. Our original LC-MS/MS analysis 
identified all eight subunits of the TRiC/CCT complex co-precipitating with M72 
expressed in in NIH3T3 cells (Table 1).  I repeatedly observed that transfected expression 
plasmid for M72-3XFLAG was incapable of co-immunoprecipitating CCT5/ε in 
HEK293T cells. Whether this is an artifact of overexpression or indicative of a cell line 
difference, is unclear. Multiple examples of viruses that engage the TRiC/CCT complex 
have been described, including EBV [144], influenza virus [199], rabies virus [139], and 
reovirus ([200]). My experiments provide evidence that MCMV M72 is likely another 
viral client of the TRiC/CCT complex (Fig. 2.6).There is no consensus sequence 
recognition recognized for TRiC/CCT client proteins. However, some biochemical 
features, such as β-sheets content, aggregation propensity and formation of higher-order 
complexes are associated with TRiC/CCT binding [126]. Little information is available 
about the structure of M72. Previous bioinformatics studies [100], as well as initial 
bioinformatic analysis using structure prediction tools, suggest the presence of multiple 
β-sheets in M72. Moreover, my data indicates that M72 is capable of forming higher-
order oligomers or aggregates (Fig. 2.6D, 2.7B), and this feature correlates with M72’s 
ability to associate with TRiC/CCT subunits (Fig. 2.7C), further supporting M72 as a 
substrate of the TRiC/CCT complex. Since M72 augments virus replication and is not an 
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essential MCMV gene, identification of other MCMV (and HCMV) essential gene 
products as TRiC/CCT clients may provide the rationale for development of TRiC/CCT 
inhibitors as potential antiviral compounds.  
In this report, I characterized the previously unexplored MCMV protein M72. 
Previous studies have established roles for other designated dUTPase genes among 
herpesviruses, and future efforts will focus on identifying the specific molecular 
mechanism of M72 function during infection. It will be important to determine whether 
the multiple isoforms of M72 protein have distinct functions during infection and how 
each contributes to pathogenesis. Contribution and characterization of host proteins 
identified here as candidate M72-interacting proteins, will provide insight into the 




 Chapter 3:  Murine Cytomegalovirus M72 co-opts components of 
CCR4-NOT transcriptional complex and contributes to viral 
replication3  
3.1 INTRODUCTION 
Carbon catabolite repression 4 (CCR4)-negative on TATA-less (NOT) is a large 
multi-subunit complex that is highly conserved across eukaryotes [145, 146]. It has eight 
core subunits in mammalian cells and nine in yeast. The core complex in humans consists 
of CNOT1, CNOT2, CNOT3, CNOT4, CNOT6/6L, and CNOT7/8 and CNOT9 subunits 
[147, 148]. Additional subunits in the human CCR4-NOT complex include CNOT10, 
CNOT11 and TAB182, although, association with these depends on conditions [147, 150, 
151]. This complex plays an important role in multiple processes. Transcriptional 
regulation, protein modification and deadenylation of mRNAs are some well-studied 
functions of this complex.  
CNOT1 is the largest subunit of the CCR4-NOT complex and is involved in 
structural assembly [154]. CNOT1 lacks enzymatic activity however; it is involved in 
diminishing deadenylase activity in cell. CNOT1 depletion is also implicated in turnover 
of processing bodies (P bodies), cytoplasmic structures, involved in RNA turnover in the 
cell [156]. CNOT1 via its interaction with RNA-binding proteins mediates transcription 
repression [150, 158]. CNOT2 possesses a conserved NOT-box at its carboxyl terminus. 
Although CNOT2 is not catalytically active by itself, it contributes to deadenylase activity 
in cells [156]. CNOT6L encodes a conserved deadenylase domain at its carboxyl terminus 
and a leucine-rich-repeat (LRR) domain at its amino-terminus [163]. The paralog CNOT6 
                                               
3 Following authors contributed to experiments in this chapter – Sandhya Gopal (SG), Amanda Y. Xia 
(AX) and Jason W. Upton (J.W.U.). SG and JWU designed the experiments. AX and SG performed the 
experiments. SG wrote this dissertation chapter. 
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is not associated with CNOT6L in the same complex [151], and these proteins are mutually 
exclusive. Human CNOT6L prefers poly(A) RNA in contrast to poly(A) DNA for activity 
in in vitro deadenylation assays revealing substrate specificity [214]. This proteins has a 
role in cell proliferation in murine fibroblasts [165]. CNOT6L was identified as a candidate 
that regulates PTEN, a tumor suppressor protein. In addition, copy number losses in 
CNOT6L were found in human colon adenocarcinoma samples [215].  
The 182-kDa Tankyrase binding protein (TAB182) or Tankyrase 1 binding protein 
1 (TNKS1BP1) was previously identified as a component of the CCR4-NOT complex 
[151] but not in all condition [150]. TAB182 was primarily recognized in a yeast-two 
hybrid screen as an interacting partner and novel acceptor of Tankyrase 1 [216]. Some 
reports have suggested a role for TAB182 in the DNA damage response [171, 172], but the 
mechanism is not clear. TAB182 was also suggested to contribute to actin cytoskeleton 
rearrangement and cancer cell invasion [174]. Little information is available on role of 
TAB182 in the context of a component of CCR4-NOT complex.   
Human Cytomegalovirus (HCMV), a beta herpesvirus, causes significant morbidity 
and mortality in immunocompromised patients including hepatitis, retinitis, pneumonitis 
and even death [77]. Congenital HCMV infection is associated with progressive 
sensorineural hearing loss, mental retardation and other complications [183]. The cost 
associated with care of HCMV-infected children is prohibitively high. Hence, development 
of an HCMV vaccine has been designated as a priority in the United States [184]. 
Identifying and understanding the role of host factors that contribute to beta herpesvirus 
infection, is important to tackling issues associated with HCMV. Herpesviruses are highly 
species-specific, which makes it challenging to study the contribution of individual genes 
in the context of natural host. To facilitate this process, MCMV is a biologically and 
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genetically similar virus utilized in mice as a small animal model. Mice are easily available, 
cost-effective and well-characterized model system to study CMV biology [80]. 
Additionally, MCMV and HCMV are genetically similar with many homologues genes 
[187, 188].  
My studies have focused on a core MCMV gene M72, previously designated as a 
deoxyuridine 5’ triphosphate pyrophosphatase (dUTPase) homolog [189]. In my previous 
report, I identified M72 as a catalytically inactive as a dUTPase homolog, opening up the 
possibility for alternate roles in MCMV replication. I constructed two-independent stop 
mutants of M72, (M72StopS and M72StopN) and showed that M72 augments the growth 
of virus in culture, in a cell-type dependent manner. I demonstrated that M72 augments 
virus replication in the natural host in the early acute phase of infection and has a complex 
protein expression pattern during infection. To begin to understand the function of M72, I 
took a proteomics approach. I identified subunits of a eukaryotic chaperonin complex 
TRiC/CCT as M72 candidate interacting proteins and established that TRiC/CCT 
contributes to M72 protein folding [1].  
Here I have continued investigating other M72 interacting host proteins identified 
from the same proteomic screen. I had previously reported enrichment of CNOT2 and 
CNOT6L in M72-3XF samples [1] and investigated whether other components of the 
hetero-oligomer CCR4-NOT transcription complex were present. I analyzed data from 
additional enriched bands and identified CNOT1 and TAB182 as novel candidate-
interacting proteins. Co-immunoprecipitation experiments helped validate and map the 
interaction of M72 with components of the CCR4-NOT transcription complex.  
To elucidate the role of this complex during viral replication, I silenced CNOT1 
and TAB182 and evaluated MCMV growth. I found that CNOT1 is necessary for wild type 
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(WT) MCMV infection at both high and low multiplicities of infection (MOI). The 
M72StopS mutant grew to levels comparable to WT virus later during high (MOI) infection 
but was attenuated compared to WT in low MOI infections. TAB182 silencing had no 
effect on WT and M72StopS replication compared to the relevant control. I found that 
CNOT1 and TAB182 protein expression was comparable between WT and M72StopS 
mutant during infection. This is the first report to demonstrate the role of CNOT1 relevant 
to MCMV biology. Thus, M72 is involved at least partially in CNOT1 mediated function 
during MCMV infection.  
3.2 RESULTS  
3.2.1 Identification of components of CCR4-NOT transcriptional complex as 
interacting partners of MCMV M72  
To understand the function of M72, I utilized the data from the proteomics approach 
previously described [1]. Briefly, M72-3XFlag or control plasmid was transfected into 
NIH3T3 fibroblasts. FLAG-immunoprecipitates were prepared, resolved by 10% SDS-
PAGE and stained. Multiple bands were observed in the M72-3XFLAG sample relative to 
the vector control (Fig. 3.1). A region of each lane in which multiple bands were 
differentially enriched, corresponding to approximately 55-75 kDa, and 150-250 kDa were 
excised from each sample, subjected to in-gel tryptic digestion and LC-MS/MS analysis. 
Comparison with the UniProt mouse reference genome helped to generate a list of 109 total 
unique proteins. I excluded proteins of low confidence representation, low abundance, 
those enriched in the control sample and subunits of TRiC/CCT complex previously 
described [1]. A significant enrichment for components of a large multi-subunit complex 
called the CCR4-NOT transcriptional complex and a protein called Tankyrase-1 Binding 
Protein (TAB182) was observed in M72-containing immunoprecipitates. I had previously 
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reported two subunits of the CCR4-NOT transcription complex, specifically CNOT2 and 
CNOT6L were enriched in the 55-75 kDa bands. These and other proteins identified in 
bands from the 150-250 kDa region were used to generate a more comprehensive list of 






Figure 3.1: Analysis of immunoprecipitates from M72 transfected cells. 
NIH3T3 fibroblasts were transfected with M72-3XFLAG and the corresponding empty 
vector control. Whole cell lysates were immune precipitated with the FLAG antibody, 
eluted, fractionated on a 10% SDS-PAGE gel and stained with Coomassie Blue stain. The 
differential bands on the gel in the M72-3XF lane and the corresponding area of Empty 
Vector control lane were subjected to LC-MS/MS analysis. The letters A, B, C indicate gel 






Table 3.1: Expanded candidate M72-interacting proteins identified by mass 
spectrometry. 
List of candidate proteins generated by subjecting the gel fragments indicated in Figure 3.1 
to LC-MS/MS analysis. Candidate proteins, their molecular mass, gel fragments from 
which they were obtained, and total peptide spectral counts are indicated in the table.   
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3.2.2 Validation and mapping of interaction of MCMV M72 with components of 
CCR4-NOT transcriptional complex 
To confirm the results of the MS experiment, I performed co-tranfections, co-
immunoprecipation and immunoblotting experiments in the HEK293T cell line. I utilized 
full-length Human (Hs) GFP-CNOT1, GFP-CNOT2 and GFP-CNOT6L expression vector 
constructs along with plasmids expressing M72-3XFLAG full-length and a series of 
carboxyl-terminal truncations of M72 (described earlier [1]). My MS experiment was 
performed in NIH3T3 murine fibroblast cells, with the human expression constructs for 
transient transfection assays. The human GFP-CNOT subunit expression constructs were 
readily available and the murine and human CNOT 1, 2 and 6L subunit proteins were 
almost identical based on pairwise sequence alignment (Table 3.2) so these plasmids were 
used for transient transfection assays.  
I co-transfected GFP-CNOT1 and M72-3XFLAG full-length along with a series of 
carboxyl terminal truncations of M72 (Fig. 3.2 D) and performed co-immunoprecipitation. 
After immunoblotting, I observed that GFP-CNOT1 co-immunoprecipitated with full-
length M72-3XFLAG, but not with the corresponding FLAG empty vector control 
construct (Fig. 3.2A). This suggests that GFP-CNOT1 interacts with M72-FLAG 
specifically. The binding of M72(1-390) was comparable to full-length M72(1-401). However, 
there was a decrease in co-immunoprecipitation of GFP-CNOT1 with M72(1-339), even 
when the expression of GFP-CNOT1 in the whole cell lysate was comparable in both 
samples. Therefore, the M72 region between amino acids (aa) 340 to 390 augments 
interaction with CNOT1. Binding of M72-3XFLAG to GFP-CNOT1 was comparable for 
carboxyl terminal aa deletions from M72(1-339) to M72(1-199). A markedly diminished co-
immunoprecipitation of GFP-CNOT1 with M72(1-172) and completely loss for fragments 
(1-136) and (1-107) was observed. The expression of GFP-CNOT1 was comparable in 
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corresponding whole cell lysates transfected with M72-3XFLAG fragments (1-199), (1-
172), (1-136) and (1-107). These results suggest that M72 aa 173 to 199 additionally 
augment interaction with GFP-CNOT1, and, that M72 aa region 137 to 172 is necessary 
for interaction with GFP-CNOT1.  
I performed a similar co-transfection and co-immunoprecipitation experiments for 
Human GFP-CNOT2 with M72 full length and carboxyl-terminal truncations. 
Immunoblotting revealed that GFP-CNOT2 co-immunoprecipitated with full-length M72-
3XFLAG (Fig. 3.2B), suggesting interaction, and this was comparable to the M72(1-172) 
construct with a deletion of aa 173 to 401 at the carboxyl terminus. GFP-CNOT2 co-
immunoprecipitation was markedly decreased for both M72(1-136) and M72(1-107) even when 
its expression in the two corresponding whole cell lysate sample was comparable with 
M72(1-172), M72(1-199) and M72(1-226). Thus the M72 region between aa 137 to 172 is likely 
necessary for interaction with GFP-CNOT2.  
In the context of human GFP-CNOT6L, I performed a comparable experiment as 
described above with M72 full-length and carboxyl-terminal truncations. We observed that 
GFP-CNOT6L co-immunoprecipitated with M72-3XFLAG full-length (Fig. 3.2C) 
suggesting binding. This interaction was comparable with the M72(1-172) construct, but 
completely lost for fragments M72(1-136) and M72(1-107). Therefore, aa 137 to 172 are needed 
for efficient binding of M72-3XFLAG with GFP-CNOT6L. An improved co-
immunoprecipitation of GFP-CNOT6L with M72(1-390) compared to M72 full-length was 
not reproducible (data not shown). These results (summarized in Fig. 3.2 E) suggest the 
interaction of M72 with components of CCR4-NOT transcription complex is complex and 




Protein pairs compared Pairwise % identityᵃ 
Hs and Mm CNOT1 99.3 
Hs and Mm CNOT2 (full)ᵇ 96.6 
Hs and Mm CNOT6l 98.0 
Table 3.2: Pairwise percentage identity at amino acid level calculated with Geneious 
6.1.8.  
ᵃIdentity is the percentage of amino acids with a direct match in the alignment. 









Figure 3.2: Validation and mapping of MCMV M72 interaction with components of the 
CCR4-NOT transcription complex. 
A, B and C) IB analysis for FLAG, GFP, and actin in IP and WCL from HEK293T cells 
co-transfected with the indicated 3XFlag-tagged M72 plasmids and GFP-CNOT1 (A), 
GFP-CNOT2 (B) and GFP-CNOT6L (C). D) Schematic diagram of epitope-tagged M72 
carboxy-terminal truncation mutants. The dark grey box indicates putative ‘dUTPase’ 
domain. The light grey box indicates the 3XFlag epitope tag. Numbers denote amino acids. 
E) Schematic diagram summarizing the interaction of M72 with components of CCR4-




3.2.3 Knockdown of CNOT1 reduces WT to comparable level as M72StopS mutant 
at late time during replication.  
I identified and validated components of the CCR4-NOT complex as interacting 
proteins of MCMV M72. Therefore, I sought to understand their role in viral replication 
by transiently disrupting the expression of CNOT1 and TAB182 independently in murine 
fibroblasts and investigating their effect on viral yield. I previously generated and 
characterized two independent recombinant viruses designated as M72StopS and 
M72StopN mutants. These mutants have engineered stop codons inserted within the M72 
gene. I identified that both are  attenuated comparably by about tenfold at both high and 
low multiplicity of infection in murine fibroblasts (NIH3T3) compared to WT MCMV  [1].  
Infection with WT virus would allow me to assess the contribution of CNOT1 and TAB182 
to MCMV infection. Additionally, infection with any one of the M72 mutants will facilitate 
understanding of the role of M72 in virus biology. Therefore, I used WT and M72StopS 
recombinant virus for infections. 
In a CNOT1-knockdown background, I infected at both high (Fig. 3.3 A) and low 
(Fig. 3.3C) multiplicities of infection (MOI) and collected samples at the indicated time 
points. Quantitation of viral yields showed that at the high MOI of 5 PFU/cell WT MCMV 
was attenuated by about 100-fold at 24 hours post infection (h.p.i.) and by about 10 fold at 
48 h.p.i. compared to the scrambled siRNA control suggesting that CNOT1 contributes to 
MCMV infection (Fig. 3.3A). Using a low MOI (of 0.05 PFU/cell), revealed similar trends 
where the WT virus grew at lower levels in CNOT1 knockdown cells compared to the 
scrambled siRNA transfected cells (Fig. 3.3C). Taken together, these results indicate that 
CNOT1 contributes to WT MCMV replication independent of replication kinetics.  
To understand the role of M72 in the context of CNOT1, I assessed growth of 
M72StopS recombinant virus. At the high MOI infection in CNOT1 knockdown cells, the 
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mutant was attenuated compared to WT by about five fold at 24 h.p.i. However, at 48 h.p.i., 
the replication of the M72StopS mutant was comparable to wild type virus in CNOT1 
knockdown background (Fig. 3.3A). Importantly, in the scrambled siRNA control cells, 
the M72StopS is defective compared to WT virus at both 24 and 48 h.p.i. This suggests 
that the modest difference in viral titers between WT and M72StopS is alleviated upon 
knockdown of CNOT1 later during replication. The low MOI experiment (Fig. 3.3C) 
yielded slightly different observations. M72StopS replication in this setting was attenuated 
compared to WT MCMV both in the control cells in the CNOT1 knockdown background 
at 24, 48 and 72 h.p.i. (Fig. 3.3C). However, it is noted that the attenuation of M72StopS 
compared to WT in control cells is about 10-fold, and this difference is reduced to about 
3-fold in CNOT1 knockdown background in a low MOI setting. Knockdown of CNOT1 
was confirmed for experiments at both MOIs (Fig. 3.3B and D).Taken together, these 
results suggest that the knockdown of CNOT1 reduces WT replication to same level as 
M72StopS in a replication kinetics dependent manner. Additionally, CNOT1 mediated 
biology is involved partially in M72 function. 
Similarly, NIH3T3 cells were transiently transfected with TAB182 (Fig. 3.3 E) and 
in parallel control (SCR) siRNAs, infected with WT and M72StopS MCMV at high MOI 
of five PFU per cell and viral yields determined. WT virus grew at about the same level in 
control and TAB182 knockdown cells (Fig. 3.3E), suggesting that TAB182 does not 
contribute to MCMV replication. M72StopS replication was attenuated compared to WT 
virus by about 10-fold in both control and TAB182 knockdown cells (Fig. 3.3E). Western 
blotting confirmed TAB182 knockdown (Fig. 3.3F). This indicated that the attenuation of 
M72StopS in murine fibroblasts is independent of TAB182. A small two-fold attenuation 
in both WT and M72StopS viruses in TAB182 knockdown background was observed 
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compared to the scrambled control cells only at 48 h.p.i. However, its role in virus biology 
remains unclear. Taken together, these results indicate that TAB182 is not involved in both 






Figure 3.3: Knockdown of CNOT1 reduces WT to comparable level as M72StopS at 
late time during replication in cell culture.  
A and C) NIH3T3 cells were transiently transfected with scrambled (SCR) control or 
CNOT1  siRNAs E) NIH3T3 cells were transiently transfected with SCR or TAB182 
siRNAs. A, C and E) NIH3T3 cells were infected with WT or M72StopS MCMV 
recombinant viruses at 5 PFU/cell (A and E) or 0.05 PFU/cell (C). Samples were collected 
at indicated time points and viral yields were determined by plaque assay. B, D and E) 
NIH3T3 cell lysates were collected in parallel for A, C and E, respectively, at 48 h.p.i. by 
addition of SDS lysis-buffer, boiled, analyzed on 4-20% TGX SDS-PAGE gel, transferred 
to a nitrocellulose membrane and immunoblotted with the indicated antibodies. Each data 
point represents n = 3 replicates. 
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3.2.4 Expression of components of CCR4-NOT complex is comparable between WT 
and M72StopS replication. 
My earlier results (Fig. 3.3) suggested that CNOT1 subunit is required for WT 
MCMV infection and that CNOT1 mediated biology is involved partially in M72 function. 
Therefore, I sought to understand the expression of components of CCR4-NOT complex 
during virus replication. Murine fibroblasts were either mock infected or infected at high 
MOI with WT and M72StopS, and cell lysates were collected. Immunoblotting revealed 
that levels of CNOT1, CNOT2, CNOT7 and TAB182 were comparable between mock, 
WT and M72StopS at the indicated time points during infection. A decrease in CNOT1, 
CNOT2 and TAB182 in WT- and M72StopS-infected cells was observed at 48 h.p.i. 
compared to mock infected cells, but a corresponding actin decrease also was noted. This 
suggested that it is possibly due to cytopathic effects of viral replication. A modest increase 
in expression of TAB182 at 24 and 48 h.p.i. was observed in mock, WT- and M72StopS-
infected cells compared to zero and 12 h.p.i. but it was independent of M72. Therefore, 
infection by MCMV does not appear to affect CNOT1, CNOT2, CNOT7 and TAB182 




   
Figure 3.4: CNOT1, CNOT2, CNOT7 and TAB182 are expressed at comparable levels 
during WT and M72StopS replication in murine fibroblasts. 
NIH3T3 cells were infected with mock or WT or M72StopS recombinant viruses at 5 
PFU/cell, lysates were collected at indicated time points and analyzed by immunoblotting 




3.2.5 M72 associates with CNOT1 during virus replication. 
My initial data suggests that M72 and CNOT1 interact in isolation. I next sought to 
determine if CNOT1 interacts with M72 during virus replication. To answer this I utilized 
a previously described M72-3XFLAG epitope tagged recombinant virus [1]. Murine 
fibroblasts were infected with WT and M72-3XFLAG MCMV in parallel at an MOI of 5 
PFU/cell for respective virus and lysates were collected at 24 h.p.i. Upon performing 
FLAG immunoprecipitation (Fig. 3.5A), there is some background binding of CNOT1 to 
FLAG beads in WT virus infected samples. However, there is a definite enrichment of 
CNOT1 in the M72-3XFLAG virus infected lysates (Fig. 3.5A). A reverse CNOT1 
immunoprecipitation (Fig. 3.5B) demonstrated the presence of M72-3XFLAG specifically 
in the corresponding virus infected sample and not in the WT MCMV infected sample. 




      
Figure 3.5: M72 associates with CNOT1 during virus replication. 
NIH3T3 cells were infected with WT or M72-3XFLAG MCMV in parallel at MOI of 5 
PFU/cell and lysates were collected at 24 h.p.i. FLAG A) or CNOT1 B) 
immunoprecipitation was performed with corresponding normal mouse (NM) A) or normal 
rabbit (NR) B) IgG controls. Samples were boiled in SDS-lysis buffer, separated on 4-20% 






In this chapter, I utilized candidate proteins CNOT2 and CNOT6L identified earlier 
[1] and analyzed additional bands enriched in M72-3XF immunoprecipitates (Fig. 3.1). 
Components of the CCR4-NOT transcription complex and TAB182 were identified as 
candidate interacting proteins of MCMV M72 (Table 3.1). I used M72 full length and 
carboxyl-terminal truncation constructs (Fig. 3.2D) along with Hs CNOT1, Hs CNOT2 
and Hs CNOT6L. Co-immunoprecipitation experiments were used to validate the 
interactions. Association between M72 and components of CCR4-NOT complex were 
confirmed. I was unable to co-immunoprecipitate other subunits of this complex in the 
initial mass spectrometry experiment, but it is likely that some other subunits are part of 
this complex via an indirect interaction. This is the first account of interaction between 
CCR4-NOT complex components and herpesvirus proteins. In addition, there are very few 
published reports regarding involvement of this complex with viruses. There are examples 
of HPV E6 protein interacting with CNOT1, CNOT2 and CNOT3 [179], and adenovirus 
E1B55K protein co-immunoprecipitating with CNOT1 [178]. Therefore, a precedence for 
DNA virus interaction with CCR4-NOT complex exists.  
I mapped the interaction of M72 with CNOT1 (Fig. 3.2A), CNOT2 (Fig. 3.2B) and 
CNOT6L (Fig. 3.2C) subunits. Amino acids 173-199 and 340-390 of M72 enhance binding 
with CNOT1, and amino acids 137-172 of M72 are necessary for binding with CNOT1 
(Fig. 3.2A and E). Amino acids 137-172 of M72 are necessary for interaction with CNOT2 
(Fig. 3.2B and E) and CNOT6L (Fig. 3.2C and E). These results imply a multi-partite 
interaction between M72 and CNOT1, whereas a single region of interaction between M72 
and CNOT2 and CNOT6L was observed. Taken together, multiple regions of M72 are 
involved in mediating binding with the entire CCR4-NOT complex. A similar example for 
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this is seen in the host protein Tob along with BTG. The Tob/BTG families of proteins are 
transcriptional cofactors and implicated in cell growth and differentiation. Tob is suggested 
to form a bridge between CNOT1 and CNOT7 whereas BTG has a single region 
contributing to interaction with CNOT7 [217].   
 To begin to understand the contribution of components of CCR4-NOT complex on 
MCMV replication, I transiently silenced CNOT1 and TAB182 in murine fibroblasts, 
infected these cells with WT and M72StopS recombinant viruses, and evaluated viral 
growth. Knockdown of CNOT1 diminished WT MCMV replication independent of 
kinetics of infection (Fig. 3.3A and C). This implies that CNOT1 is a host factor required 
for MCMV replication. Two illustrations among RNA viruses, HCV [180] and Influenza 
A virus [181], show that knockdown of CCR4-NOT complex components diminishes viral 
replication. CNOT1, CNOT2, CNOT3 and CNOT6L are required for HCV replication 
[180]. In IAV, silencing of CNOT4 subunit diminishes viral replication. CNOT4 subunit 
is a RING-domain containing E3 ligase and post-translationally modifies the nucleoprotein 
of IAV, potentially providing structural stability, promoting RNA transcription and 
replication [181]. The above three examples (MCMV, IAV and HCV) build a case for 
categorizing CNOT1 as a required host factor. However, in complete contrast, knockdown 
of CNOT1 promotes adenovirus replication. Though the mechanism is not clear, CNOT1 
may promote adenovirus early protein expression [178]. Thus, CNOT1 is a very dynamic 
host factor in virus replication. Owing to its association with multiple subunits and 
implications in diverse cellular processes [154], its contribution most likely depends on the 
type of sub-complex formed with each type of virus. This also implies that CNOT1 is a 
likely starting point, and continued investigations of other subunits in this complex will 
delineate their role in MCMV replication.      
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In the context of M72, we observed that CNOT1 knockdown reduces the replication 
of WT virus to comparable levels as M72StopS late in viral replication when infected at a 
high MOI (Fig. 3.3A). Intriguingly, in a low MOI infection, CNOT1 knockdown does bring 
down WT viral titers to M72StopS (Fig. 3.3C) at least up to the time points tested. The 
difference in viral replication levels between WT and M72StopS was diminished (Fig. 3.3 
C) in the CNOT1-knockdown background. This exciting result indicates a genetic 
connection between CNOT1 and M72 biology. However, it does not completely explain 
the attenuated phenotype of the M72StopS recombinant virus. It is possible that other 
subunits like CNOT2 and CNOT6L, which have not been entirely investigated, have a role 
to play in M72 biology. Alternatively, an entirely independent host factor might be 
contributing to M72 biology. A systematic screen to identify cellular determinants 
interacting with M72 during infection might be one way to approach this issue in the future. 
I observed that TAB182 is dispensable for WT MCMV replication and any 
potential M72 function in murine fibroblasts (Fig. 3.3E). This negative data is important 
because it suggests specificity to CNOT1-mediated reduction of WT to M72StopS level 
(Fig. 3.3 A). TAB182 and CNOT1 independent knockdowns have distinct effects on WT 
and M72StopS replication. Some reports suggest that TAB182 commonly co-
immunoprecipitates with components of the CCR4-NOT complex, while others report a 
conditional effect [150, 151]. Other than its initial identification in the proteomic screen, 
the co-immunoprecipitation of TAB182 with M72 has not been performed. Additionally, 
experiments to determine if TAB182 co-immunoprecipitates as a part of the CCR4-NOT 
complex has not been confirmed. At least in murine fibroblasts, TAB182 does not appear 
to contribute to MCMV replication. However, since MCMV and HCMV exhibit a wide 
range of tissue tropism [218], TAB182 may participate in a different cell type. One report 
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showed that adenovirus E4orf6 protein degraded TAB182 during infection. In addition, 
knockdown of TAB182 promoted Adenovirus infection [178]. Thus, there is precedence 
in literature for this novel host factor’s involvement in DNA virus replication.   
Since MCMV requires CNOT1 during infection, I hypothesized that infection 
upregulates the expression of components of CCR4-NOT complex. Analysis of protein 
amounts revealed that CNOT1, CNOT2, CNOT7 and TAB182 levels during high MOI 
infection are comparable between mock, WT- and M72StopS- infected samples (Fig. 3.4). 
Levels of other components of the complex, especially CNOT6L, identified in my screen 
will be examined during MCMV infection.  
Utilizing an epitope-tagged M72-3XFLAG recombinant virus, I demonstrated that 
M72 and CNOT1 interact during MCMV replication. It remains to be investigated if other 
components of the CCR4-NOT complex, especially CNOT2 and CNOT6L co-
immunoprecipitate with M72.   
Based on my current results, I believe that M72 co-opts CNOT1 and possibly other 
components of the CCR4-NOT transcription complex during virus replication. Future work 
will focus on contribution of CNOT2 and CNOT6L to MCMV infection and M72 biology. 
The CCR4-NOT, complex has been implicated in multiple cellular processes [154]. 
CNOT1 and CNOT2 lack enzymatic activity by themselves [147]. However, I identified 
and validated interaction of M72 with CNOT6L, a subunit with deadenylase activity [147]. 
I suggest that M72 utilizes its association with CCR4-NOT complex to regulate the 
turnover of mRNA substrates via poly (A) tail deadenylation and subsequent degradation. 
Future work will investigate this hypothesis and focus on the mechanism of CNOT1 
requirement to MCMV and M72 biology.  
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Importantly, my results suggest that it is imperative to assess if interaction with 
components of the CCR4-NOT complex is conserved for HCMV and possibly other 
members of the herpesviruses. Future mechanistic studies will help address this issue and 




Chapter 4:  Conclusions and Future Directions 
4.1 CHARACTERIZATION OF MCMV M72 AND IDENTIFICATION OF TRIC/CCT AS A 
NOVEL HOST FACTOR 
4.1.1 Summary 
The goal of my dissertation research was to understand the beta herpesvirus 
dUTPase homolog, M72, based on the interesting roles among other members of 
herpesviruses. I showed that M72 is not enzymatically active as a dUTPase implying 
alternate function/s in replication. M72 is expressed as a leaky-late gene and has a complex 
expression profile with multiple isoforms. I established for the first time that a beta 
herpesvirus dUTPase homolog augments virus replication in cell culture and in the natural 
host. M72 was identified as a client of the TRiC/CCT chaperonin complex and forms 
homo-oligomers [1].     
4.1.2 Future Directions 
My result that M72 is not active as a dUTPase was not surprising, since M72 lacks 
five out of the six conserved catalytic motifs. However, the presence of multiple isoforms 
during infection was intriguing. My initial examination suggests that isoforms are made 
from internal methionine positions. This needs to be confirmed in the future by 
mutagenesis. Generating a panel of internal methionine point mutants and an M72 
construct in which all the internal methionine positions are mutated leaving behind only 
the starting methionine will be valuable reagents. It will be important to build and 
characterize the phenotype of such an ‘internal methionine less’ M72 recombinant virus 
and compare it with the existing M72Stop mutants. Based on bioinformatics predictions, 
M72 has a nuclear localization signal (NRRKKLKRK) between amino acids 5 and 13 from 
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the amino-terminus of the protein (utilizing NucPred online tool [219]). This suggests that 
the full-length protein has a nuclear localization. The question then arises regarding 
localization of the internal methionine isoforms of M72. A panel of M72 constructs 
initiating from internal methionine position has been constructed. These existing constructs 
and the new panel of point mutants could be used to assess the localization of multiple M72 
protein isoforms. Further, recombinant viruses corresponding to the internal methionine 
constructs can be generated and the phenotype of these can be characterized in different 
cell types.  
My data suggests that M72 augments the replication of virus in a cell culture 
system. The current M72Stop mutants block only the three longest isoforms. This might 
explain the modest attenuation I observed compared to WT replication. It will be valuable 
to generate a more refined stop mutant further downstream of M72 than existing ones in 
which all three reading frames are interrupted, characterize the growth of this new 
recombinant virus and compare the phenotype with previous M72Stop mutants.   
I identified an interaction of M72 with the TriC/CCT complex and showed that the 
chaperonin complex aids in protein folding. It is possible that other MCMV proteins utilize 
the chaperonin complex for folding and assembly. Co-immunoprecipitation of the 
chaperonin complex during infection and subsequent proteomic analysis is one approach 
to identify viral proteins associating with TRiC/CCT. Extension to HCMV also will be 
valuable. The TRiC/CCT complex has been studied in the context of protein aggregation 
disorders [220] and cancer progression [221] and efforts are being made to identify 
inhibitors of this complex. If essential viral genes are identified in MCMV or HCMV as 
TRiC/CCT client proteins, this chaperonin complex will likely be added to the list of 
therapeutic targets for HCMV.   
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4.2 COMPONENTS OF THE CCR4-NOT COMPLEX AS NOVEL HOST FACTORS 
CONTRIBUTING TO MCMV REPLICATION.  
4.2.1 Summary 
Along with other M72 candidate interactions from our previous proteomic screen 
[1], we identified components of the CCR4-NOT complex. I validated and mapped the 
interaction of M72 with CNOT1, CNOT2 and CNOT6L. CNOT1 is required for WT 
MCMV replication and at least partially contributes to M72 biology. My current working 
model is that M72 co-opts components of CCR4-NOT complex to mediate its own 
function (Fig. 4.1).      
4.2.1 Future Directions 
I utilized a series of carboxyl-terminal truncations of M72 and mapped the 
interaction with CNOT1, CNOT2 and CNOT6L. In the future, a complementary set of 
amino-terminal truncations and/or specific deletions of the indicated M72 interacting 
regions may be needed. These can be used to confirm my initial mapping experiments. It 
might also be significant to map the interaction on each of the CCR4-NOT complex 
subunits with M72 by generating truncations of CNOT1, CNOT2 and CNOT6L and 
performing reverse co-immunoprecipitations. I have not investigated the role of CNOT2 
and CNOT6L in MCMV replication. Transient or stable independent knockdowns of these 
two subunits and similar experiments (e.g., Fig. 3.3) to evaluate viral growth in WT and 
M72StopS might be useful. Since my data suggests that expression of the CCR4-NOT 
components is comparable before or during infection, it will be interesting to assess 
localization of CNOT1, CNOT2 and CNOT6L subunits and M72 during infection. I 
speculate that M72 might be co-localizing with at least CNOT1 and some other 
components of this complex. Localization of the CCR4-NOT complex components upon 
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infection or during specific time points during viral replication can provide further 
mechanistic insight. I have described generating the M72-3XFLAG tagged recombinant 
virus previously [1]. M72-HA and M72-mCherry tagged two independent recombinant 
viruses also have been generated. Any of these three recombinant viruses can be utilized 
to assess localization of M72 and the CCR4-NOT complex components. In addition, co-
immunoprecipitation experiments during infection in future might yield information on the 
nature of the CCR4-NOT complex subunits interacting with M72 during virus replication.    
CNOT1 and CNOT2 by themselves do not have any enzymatic role. However, 
these proteins contribute to deadenylase activity in human cells [156]. I have validated and 
mapped the interaction of M72 with CNOT6L, a subunit with known deadenylase activity 
[154]. Therefore, I hypothesize that M72 utilizes components of the CCR4-NOT 
complex and deadenylates host and/or viral mRNAs during infection (Fig. 4.1). There 
are examples in literature of CNOT1 interacting with specific RNA-binding proteins and 
mediating turnover of mRNA substrates [150, 158]. It is also likely that M72 interacts 
independently with an RNA-binding protein. One of the proteins enriched in M72-FLAG 
precipitates was the RNA-binding motif protein 14 (RBM14). RBM14 contains two RNA 
recognition motifs, localizes in paraspeckles in the nucleus and functions as a general 
nuclear coactivator [222]. Since, RBM14 was at low abundance (zero in the empty vector 
versus 12 in M72-3XFLAG total spectral counts), I did not pursue it here. However, with 
my current data, it is one of the possibilities to explore. Another speculation is that M72 
by itself can bind to mRNAs. If the above-mentioned hypothesis is true, current carboxyl-
terminal M72 truncations can be used to map the deadenylase activity and assess if 




Figure 4.1: Hypothetical model for M72 mediated function. 
Schematic illustrating current working model that M72 co-opts components of CCR4-NOT 
complex, specifically CNOT1, CNOT2, CNOT6L and possibly other unknown mediators. 
A hypothesis suggesting that M72 utilizes the CCR4-NOT complex components to turn 




4.3 OVERALL CONCLUSIONS 
In conclusion, through my dissertation research, I have characterized a relatively 
unknown herpesvirus gene, MCMV M72, and revealed its contribution to virus replication 
not only in a cell culture system, but also in the natural host. I identified a complex 
expression profile for M72 protein. This opens up questions related to regulation of M72 
and its isoforms. Other cytomegalovirus proteins also may be made during infection via 
internal methionine usage and it works as a viral strategy to expand its repertoire within 
the existing genomic context. I identified interactions of M72 with two novel host factors, 
TRiC/CCT and the CCR4-NOT complex. My work represents significant developments in 
the context of CMV host-pathogen interactions. Continued investigations into these novel 
host factors might expand our knowledge of drug targets against CMV and reveal intricate 




Chapter 5:  Materials and Methods 
5.1 CHAPTER 2 MATERIALS AND METHODS  
5.1.1 Plasmids and Transfections  
M72 expression constructs were generated by PCR amplification of nucleotides 
104,289 to 103,084 using the MCMV K181 bacterial artificial chromosome (BAC) 
pARK25 (Accession No. AM886412.1) [192], as template. Amplicons were cloned into 
the EcoRI and XbaI sites of p3XFLAG-CMV10 or p3XFLAG-CMV14 expression 
constructs (Sigma-Aldrich) or the EcoRI and KpnI sites of pEGFP-C1 (Clontech). 
Transfections were performed using GenJet transfection reagent (SignaGen Laboratories) 
according to manufacturer instructions. HA-CCT expression constructs [223] were a kind 
gift from Dr. Kyong-Tai Kim (Pohang University of Science and Technology, Republic of 
Korea). FLAG-tagged MHV68 ORF54 and ORF54H80A/D85N expression constructs [110] 
were a kind gift from Drs. Ting-Ting Wu and Ren Sun (University of California at Los 
Angeles). 
5.1.2 Cells and Reagents  
STO (CRL-1503), HEK293T (ATCC CRL-3216), SVEC4-10 endothelial cells 
(ATCC CRL-2181) and RAW264.7 murine macrophages (ATCC TIB-71) were 
propagated in Dulbecco’s modified Eagle’s medium (DMEM - Sigma-Aldrich) containing 
10% heat-inactivated fetal calf serum (FCS, Life Technologies, Inc.) and 1% penicillin-
streptomycin-glutamine (PSG, Life Technologies, Inc.). NIH3T3 murine fibroblasts 
(ATCC CRL-1658) were propagated in DMEM containing 10% heat-inactivated bovine 
calf serum (BCS, Life Technologies) and 1% PSG. Bone marrow-derived macrophage 
(BMDM) cultures were generated as previously described [14]. Briefly, pooled bone 
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marrow cells from flushed tibias and femurs were harvested into Dulbecco’s PBS, placed 
in culture for at least 18 hr. in DMEM containing 10% FBS, and then differentiated for 5–
7 days in DMEM containing 20% FBS and 20% L929-conditioned medium. 
Phosphonoformic acid (PFA) was from Sigma-Aldrich. 
5.1.3 Generation of recombinant viruses  
BAC mutagenesis and diagnosis was performed by recombineering as previously 
described [224]. Briefly, E. coli DH10B cell containing pARK25 and pSIM6 [225] were 
grown to an OD600 of 0.4 to 0.6, recombination functions induced by incubation at 42oC, 
and cells were made electrocompetent by multiple washes in ice cold water. The 
levansucrase (SacB) and kanamycin (Kan) genes were amplified from plasmid pTBE100 
[224] with 60 nucleotide base pair overhangs corresponding to MCMV genomic 
sequences. PCRs were treated with DpnI, and amplicons gel purified then were used to 
electroporate induced bacteria. Kanamycin-resistant, sucrose-sensitive clones were 
selected and assessed for insertion and genomic integrity by PCR and RFLP analysis. 
M72.SK (primers; SG005, 5’-
ACGGGACGCCTGCACAACGTCGGAAGGCGTCGCGACCTCGAGGAACAAAAGCAG
CAGCACAATTCGAGCTCGGTACCCGG-3’ and SG006, 5’-
ATCACGATCTTGTTGACGGTCGTATCCGGCACCGAAGCGGCGACCGACACCGGTA
CGGAGGCCATCCCGGGAAAAGTGCCACC-3’: italic indicates viral sequence) 





GAGCTCGGTACCCGG-3’ and FC002, 5’- 
ACCGCGCGGAAGAGAGAATGCGAAGCGGTCGAGACTCGTCGAACGAGGGCATCC
CGGGAAAAGTGCCACC) deletes the M72 stop codon (nucleotides 103,083 – 103,086) 
and introduces an additional 2.9 kb of sequence. Specific mutations were introduced by a 
second round of recombineering with individual amplicons generated by overlap 
extension PCR. M72StopS (primers; SG007, 5'-
ATGAAGGATCCCTTTAATATCTTCGACTAGTACGAACCTTCC-3' and SG015, 5’-
GGAAGGTTCGTACTAGTCGAAGATATTAAAGGGATCCTTCAT 3’; bold indicates 
nucleotide substitution, underline indicates diagnostic restriction enzyme recognition site) 
and M72StopN (primers; SG009, 5'-
ATGAAGGATCCCTTTAATAGCTAGCACGACGACGAACCTTCC-3' and SG016, 
5’-GGAAGGTTCGTCGTCGTGCTAGCTATTAAAGGGATCCTTCAT-3’) contain an 
engineered stop codon and a SpeI (nt 104,124 – 104,127), or an NheI (nt 104,135-
104,130) diagnostic restriction site, respectively. M72.3XFlag inserts three tandem 
FLAG epitopes at the C-terminal end of M72, and was constructed by recombineering 
with an amplicon generated by overlap extension PCR (primers; FC003, 5’-
GGACGTGTAAGTGTGTGGATTGTTG-3’ and FC009, 5’-
TGACCTAGAGAGATTACCTCTTGTCTAG using template pARK25; FC004, 5’- 




3’ template p3XFLAG-CMV-14-M72). Colonies were screened for kanamycin 
sensitivity and sucrose resistance, and positive clones were confirmed by PCR and RFLP 
analysis. PCR amplification and diagnostic restriction digest of M72 region confirmed 
the incorporation of the intended sequence in the M72 mutants. Infectious virus was 
reconstituted as previously described [224], amplified by growth in STO cells in the 
presence of 25 μg/ml 6-thioguanine (Sigma-Aldrich, St. Louis, MO), and plaque purified 
by limiting dilution. Parallel stocks were produced by infecting BALB/cJ mice with 
initial transfection supernatants of WT and M72Stop mutants (M72StopS and 
M72StopN). Infected salivary glands were harvested 14 days post infection (d.p.i.), 
sonicated, clarified and used to infect NIH3T3 fibroblasts. Viral stocks were generated, 
clarified, concentrated and titered by plaque assay as previously described on NIH3T3 
fibroblasts [224]. All viral stocks were confirmed to be GFP negative, indicating excision 
of the BAC. All M72 viral stocks were confirmed by sequencing of the recombinant 
junctions, introduced mutations, and surrounding regions.  
5.1.4 Infections, in vitro growth, and determination of viral titers  
Viral titers were determined by plaque assays performed on NIH3T3 fibroblasts. Viral 
growth in vitro was determined by infection of indicated cell lines at a multiplicity of 
infection (MOI) of 5 PFU/cell to measure single step growth kinetics, or at 0.05 PFU/cell 
to measure multiple cycles of replication. Viruses were adsorbed for 2 hr at 37oC in a 
volume of 0.4 ml. Cells and supernatants for quantitation were harvested at indicated 
times post infection, and frozen at -80oC. Samples were subjected to one round of 
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freeze/thawing, and virus was quantitated by plaque assay on NIH3T3 fibroblasts as 
previously described [224]. Organs for virus quantitation were thawed and homogenized 
by sonication. Organ homogenates were serially diluted in complete media, and the titers 
were determined by plaque assay on NIH3T3 fibroblasts as previously described [224]. 
5.1.5 Immunoblotting  
NIH3T3 fibroblasts were seeded in 35 mm dishes and infected with MCMV-M72.3XFlag 
recombinant virus at an MOI of 5 PFU/cell in the absence or presence of 200 µg/ml 
Phosphonoformic acid (PFA, Sigma). Whole cell lysates were made at the indicated time 
points by removing media, washing the cells with PBS, adding 200 μl of 1X SDS-lysis 
buffer directly on the cells and freezing the dish at -20oC. All the samples were heated at 
95ºC for 10 min, analyzed on 10% SDS-PAGE gel, immobilized on nitrocellulose 
membranes and probed with indicated antibodies.  
5.1.6 Immunoprecipitation, Immunoblotting and Antibodies  
Immunoprecipitations were performed by lysing transfected or infected cells in NP-40 
lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, and 1% NP-40, supplemented with 
c0mplete Mini EDTA free Protease inhibitor cocktail (Roche), Phosphatase inhibitor 
cocktails 2 and 3 (Sigma-Aldrich)) on ice for 20 min, and clarifying by high-speed 
centrifugation for 10 min. Supernatants were pre-cleared with Mouse IgG Agarose beads 
(Sigma), immunoprecipitated using anti-FLAG M2 affinity beads (Sigma), followed by 
elution with 20 μg of 3X FLAG peptide (Sigma). Samples were mixed with 2X- SDS 
sample buffer, boiled at 95ºC for 10 min, and resolved on 10% SDS-PAGE gels. 
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Immunoblotting was performed as previously described [224]. The following antibodies 
were used: mouse anti-FLAG M2-Peroxidase (Clone M2; Sigma-Aldrich), mouse anti-
HA-peroxidase (Clone HA-7; Sigma-Aldrich), rabbit anti-GFP (FL) (sc-8334; Santa 
Cruz), mouse anti-β-actin (Clone AC-74; Sigma), mouse anti-m123/IE1 (CROMA101; 
Center for Proteomics, University of Rijeka), mouse anti-M112-113/E1 (CROMA103; 
Center for Proteomics, University of Rijeka), mouse anti-M55 (C1 M55.01; Center for 
Proteomics, University of Rijeka ), rabbit anti-M86 (MCP – a gift from Dr. Laura 
Hanson, Texas Women’s College, Denton, TX), rabbit TCP1/CCT1 polyclonal (10320-1-
AP, Proteintech), rabbit CCT7 polyclonal (15994-1-AP, Proteintech), rabbit CCT8 
polyclonal (12263-1-AP, Proteintech), donkey anti-mouse IgG-HRP (Vector 
Laboratories), and goat anti-rabbit IgG-HRP (Vector Laboratories). Blots were visualized 
using ECL Prime Western Blotting Detection Reagent (GE Healthcare) and exposed to 
film. Digital images were generated with a CanoSCAN LIDE 700F slide/film scanner 
(Cannon) and images processed with Canvas X16 software (ACD Systems International, 
Ft. Lauderdale, DL, USA). No digital enhancements were applied.  
5.1.7 Animal infections and organ harvest  
BALB/cJ mice were obtained from the Jackson Laboratory. Animals were bred and 
maintained at the Animal Resources Center (ARC) at the University of Texas at Austin in 
accordance with the institutional guidelines. Male and female animals were used between 
7 and 12 weeks of age. Intraperitoneal (i.p.) infections were performed by injection of 105 
PFU in a volume of 0.5 ml. Upon sacrifice, organs were harvested by sterile dissection, 
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placed into 1 ml complete DMEM and frozen at -80oC before titer determination. Each 
time point represents n = 10 or 15 mice per group. All procedures were approved by the 
University of Texas at Austin Institutional Animal Care and Use Committee.  
5.1.8 dUTPase assay  
dUTPase assays were performed as previously described [110]. Briefly, epitope tagged 
M72, MHV68 ORF54 or its catalytic mutant ORF54H80A/D85N were transfected into 
HEK293T cells. Cells were lysed 36 hr post transfection in NP-40 lysis buffer on ice for 
20 min, and clarified by centrifugation. Supernatants were pre-cleared with Mouse IgG 
Agarose beads (Sigma), immunoprecipitated using anti-FLAG M2 affinity beads 
(Sigma), followed by elution with 20 μg of 3X FLAG peptide (Sigma). Five μl of 
purified FLAG-tagged proteins were incubated for indicated times at 37oC with five μl of 
5 mM dUTP (Promega) in ten μl of 2x reaction buffer (100 mM Tris pH 7.5, 20mM 
MgCl2, 20 mM DTT, 0.2 mg/ml BSA). Reactions were terminated by freezing. PCR was 
performed using the dUTP sample, along with dATP, dCTP, and dGTP to amplify a 
small region of M72 expression plasmid DNA (primers; SG020 5’-
CTTGAATTCAGCCACCATGGCGAAGCACAACAGAAGG-3’ and SG032, 5'-
CAATCTAGACTTCTCGGGACGACGCGCTTCC-3'). PCR cycle conditions were 
95oC, 2 min; 94oC, 30 sec; 65oC, 30 sec; 720C, 30 sec for 35 cycles, 72oC 10 min and 
hold at 4oC. PCR products were analyzed on 2% agarose gel.  
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5.1.9 Sample Preparation, LC-MS/MS, and Data Analysis  
M72-3XFLAG or its corresponding empty vector control p3XFLAG-CMV-14 were 
transfected into NIH3T3 fibroblasts in 10 cm dishes. Whole cell lysates were collected 24 
hr later in 1% NP-40 lysis buffer and subjected to FLAG-immunoprecipitation as 
described above. Samples were eluted using 50 μg 3X FLAG peptide (Sigma) for 30 min 
on an orbital rotator at room temperature. Eluted proteins were boiled in 1X SDS sample 
buffer, separated on a 10% SDS-PAGE gel, stained with 0.1% Coomassie-Blue dye and 
destained. Bands present in the M72-3XFLAG lane compared to the vector control were 
selected, and gel slices submitted for liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) analysis (Proteomics Core Facility, UT Austin). Gel bands were subjected 
to in-gel tryptic digest and separated by liquid chromatography on a Dionex Ultimate 
3000 nanoflow UPCL system (Thermo Scientific). Eluting peptides were directly 
analyzed by nano-electrospray ionization-tandem mass spectrometry on a Thermo 
Orbitrap Elite (Thermo Scientific) instrument for a processing time of 1 hr. Protein 
identification was provided by the University of Texas at Austin Proteomics Facility 
following previously published procedures [226]. Scaffold (version Scaffold_4.3.4, 
Proteome Software Inc., Portland, OR) was used to validate MS/MS based peptide and 
protein identifications. Peptide identifications were accepted if greater than 57.0% 
probability to achieve an FDR less than 0.5% by the Peptide Prophet algorithm [6] with 
Scaffold delta-mass correction. Protein identifications were accepted if greater than 
99.0% probability and contained at least 5 identified peptides. Protein probabilit ies were 
assigned by the Protein Prophet algorithm [7]. Proteins that contained similar peptides 
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and could not be differentiated based on MS/MS analysis alone were grouped to satisfy 
the principles of parsimony. Proteins were annotated with GO terms from 
gene_association.goa_uniprot (downloaded Jul 14, 2014) [12].  
5.1.9 TRiC/CCT substrate assay 
The substrate assay was adapted from a previously described assay [202]. Briefly, 
HEK293T cells were transfected with M72-3XFLAG. At 24 hr post transfection, cells 
were lysed in NP-40 lysis buffer on ice for 20 min, clarified by centrifugation for 10 min 
and supernatants were aliquoted into 4 parts. Samples were either mock treated or 
incubated with 15mM EDTA or 5mM MgCl2 with or without 5mM ATP for 40 min at 
room temperature. Samples were pre-cleared with normal Rabbit-IgG (Santa Cruz 
Biotech) and ProteinA/G PLUS-Agarose beads (Santa Cruz Biotech). Samples were 
immunoprecipitated using a mixture of 0.5 µg of rabbit anti-CCT8 antibody and 0.5 µg of 
rabbit TCP1 antibody and Protein A/G agarose beads overnight at 4ºC on an orbital 
rotator. Beads were boiled in SDS sample buffer at 95ºC for 10 min, resolved on 10% 
SDS-PAGE and used for immunoblotting.  
5.1.10 in vitro transcription/translation 
Assays were performed as previously described [200]. Briefly, coupled in vitro 
transcription and translation reactions were conducted using the TNT-coupled rabbit 
reticulocyte lysate (RRL) system (Promega, L4610) according to the manufacturer’s 
instructions. All open reading frame templates for in vitro transcription and translation 
were sub-cloned into the pcDNA3.1+ vector. All reactions were incubated at 30°C for 
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variable intervals depending on the experimental conditions. Reactions were supplemented 
with [35S]-methionine (Perkin Elmer, NEG709A500UC) for radiolabeling and RNasin Plus 
RNase Inhibitor (N2611). Translation reactions were terminated by four-fold dilution in 
stop buffer (20 mM HEPES-KOH, pH 7.4, 100 mM potassium acetate, 5 mM magnesium 
acetate, 5 mM EDTA, 2 mM methionine, 1 mM DTT, 2 mM puromycin) unless otherwise 
specified. Samples were then resolved by native- and SDS-PAGE. 
5.2 CHAPTER 3 MATERIALS AND METHODS  
5.2.1 Plasmids and Transfections 
M72 full-length and truncation expression constructs cloned into p3XFLAG-CMV14 and 
M72 full-length cloned into pEGFP-C1 were made as previously described [1]. Plasmid 
transfections were performed using GenJet transfection reagent (SignaGen Laboratories). 
pT7-EGFP-C1-Hs CNOT1 (# 37370), pT7-EGFP-C1-Hs CNOT2 (#37371) and pT7-
EGFP-C1-Hs CNOT6L (# 37369) were obtained from Addgene.   
5.2.2 Cells 
HEK293T cells (ATCC CRL-3216) were propagated in Dulbecco’s modified 
Eagle’s medium (DMEM - Sigma-Aldrich) containing 10% heat-inactivated fetal calf 
serum (FCS, Life Technologies, Inc.) and 1% penicillin-streptomycin-glutamine (PSG, 
Life Technologies, Inc.). NIH3T3 murine fibroblasts (ATCC CRL-1658) were propagated 
in DMEM containing 10% heat-inactivated bovine calf serum (BCS, Life Technologies) 
and 1% PSG.  
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5.2.3 Viruses  
Mouse-passaged viral stocks were titered and used for infections as previously 
described [1]. Briefly, the WT K181 MCMV containing bacterial artificial chromosome 
was utilized to generate M72StopS mutant virus by recombineering. The initial transfection 
supernatants of WT and M72StopS mutant were infected in BALB/cJ mice; salivary glands 
were harvested 14 days post infection. These organs were sonicated, and viral stocks 
generated on NIH3T3 cells.  
 5.2.4 siRNA treatment for depletion of CNOT1 and TAB182  
ON-TARGETplus SMART pool Mouse CNOT1 and Mouse TAB182 and 
scrambled control were used (GE Dharmacon). NIH3T3 cells were seeded in 6-well tissue 
culture plates at 0.3x106 cells per well. At 24 hr, media was changed to antibiotic-free 
DMEM and transfected with siRNAs diluted in Opti-MEM (Thermo Fisher Scientific) at 
concentration of 200 picomoles per μl siRNA per well in a 6-well plate using 
Lipofectamine RNAiMAX (ThermoFisher Scientific). After 24 hr, these siRNA 
transfected NIH3T3 cells were split and plated in 12-well tissue culture plates at 0.1x106 
cell per well, and used the following day for infection. 
5.2.5 Infections, in vitro growth, and determination of viral titers  
Indicated viruses were adsorbed for 2 hr at 370C in 0.4 ml volume with intermittent 
shaking. Infection of NIH3T3 cells was at 5 PFU/cell (high multiplicity of infection or high 
MOI) or at 0.05 PFU/cell (low multiplicity of infection or low MOI) as indicated. Cells 
and supernatants were harvested at the indicated times post infection and frozen at -800C. 




5.2.6 Immunoblotting  
NIH3T3 cells were mock or infected at multiplicity of infection 5 PFU/cell with 
indicated viruses. Cells were washed with PBS at the indicated time points and lysed by 
directly adding 200 μl of 1X SDS-lysis buffer, boiled at 950C for 10 min and analyzed on 
4–20% Mini PROTEAN TGX SDS-PAGE gel (Bio Rad), transferred and immunoblotted 
as previously described [1]. 
5.2.7 Immunoprecipitations, Immunoblotting and Antibodies 
Transfected and infected cells were lysed as previously described [1]. Briefly, 
NP-40 lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, and 1% NP-40, supplemented 
with c0mplete Mini EDTA free Protease inhibitor cocktail (Roche), Phosphatase inhibitor 
cocktails 2 and 3 (Sigma-Aldrich)), was added, samples were incubated on ice for 20 min 
and clarified for 10 min by high-speed centrifugation. For immunoprecipitations, lysates 
were pre-cleared with mouse IgG agarose beads (Sigma) or rabbit protein IgG (Santa 
Cruz) and Protein A/G agarose beads (Santa Cruz). Subsequently they were incubated in 
anti-FLAG M2 affinity beads (Sigma) or anti-CNOT1 antibody (Proteintech) and Protein 
A/G agarose beads overnight at 4ºC, washed and beads were boiled in 1X-SDS lysis 
buffer at 95ºC for 10 min, and resolved on 10% SDS-PAGE gels. Immunoblotting was 
performed as previously described [224]. The following antibodies were used: mouse 
anti-FLAG M2-Peroxidase (Clone M2; Sigma-Aldrich), mouse anti-m123/IE1 (IE1.01; 
Center for Proteomics, University of Rijeka), mouse anti-β-actin (Clone AC-74; Sigma), 
rabbit anti-GFP (FL) (sc-8334; Santa Cruz), rabbit anti-CNOT1 (14276-1-AP; 
Proteintech), mouse anti-CNOT2 (sc-2191c2a; Santa Cruz), mouse anti-CNOT7 (sc-
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101009; Santa Cruz), goat anti-TAB182 (N-20; sc-49261; Santa Cruz), donkey anti-
mouse IgG-HRP (Vector Laboratories), goat anti-rabbit IgG-HRP (Vector Laboratories) 
and horse anti-goat IgG-HRP (Vector Laboratories). Blots were visualized using ECL 
Prime Western Blotting Detection Reagent (GE Healthcare) and exposed to film. Digital 
images were generated with a CanoSCAN LIDE 700F slide/film scanner (Cannon) and 
images were processed with Canvas X16 software (ACD Systems International, Ft. 
Lauderdale, DL, USA). No digital enhancements were applied.  
5.2.8 Sample Preparation, LC-MS/MS, and Data Analysis  
This procedure was previously described [1]. Briefly, M72-3XFLAG or its 
corresponding empty vector control p3XFLAG-CMV-14 were transfected into NIH3T3 
cells, immunoprecipitated with FLAG-specific antibody, and eluted with 3XFLAG 
peptide. Samples were separated on SDS-PAGE gels, stained with Coomassie-Blue dye, 
destained and enriched bands in M72-3XFLAG lane selected and subjected to LC-MS/MS 
analysis. Protein identification was provided by the Proteomics core facility at University 
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